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Hippo signaling is an evolutionarily conserved pathway that restricts organ growth 
during development and suppresses regeneration in mature organs. Using a high-
throughput phenotypic screen, we have identified a potent, non-toxic, and reversible 
inhibitor of Hippo signaling. An ATP-competitive inhibitor of Lats kinases, the compound 
causes Yap-dependent proliferation of murine supporting cells in the inner ear, murine 
cardiomyocytes, and human Müller glia in retinal organoids. The compound promotes 
the initial stages of the proliferative regeneration of hair cells, a process thought to be 
permanently suppressed in the adult mammalian inner ear. In conjunction with the Tri-
Institutional Therapeutics Discovery Institute, we have thoroughly characterized the 
compound and generated a suite of over 60 derivatives with improved characteristics 
such as potency, pharmacokinetics, and specificity. Together, these compounds offer 
powerful tools for molecular investigations of development, stem cell biology, and 
regeneration; it is even plausible that drugs related to this novel thiazolimine class will 
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Hearing and balance disorders plague hundreds of millions of people across the world. 
The World Health Organization estimates 466 million people, or 6.1 % of the world’s 
population, live with disabling hearing loss1. In the United States, vestibular dysfunction 
has been reported in 35 % of individuals over the age of 402. The affected organs lie 
within the inner ear, which comprises six patches of sensory epithelia—five of which are 
dedicated to the detection of linear and rotational acceleration; the sixth, the cochlea, 
decodes complex sounds waves into neural signals, enabling hearing (Fig 1.1A). 
Because these organs lack any regenerative capability, damage accumulates over a 
lifetime, leading to the ubiquitous problems. Moreover, no therapeutic approach has 
been established for these pathologies, so our best solutions thus far involve 
preventative measures, coping strategies, and hearing aids. Over the last few decades, 
some barriers to mammalian inner-ear regeneration have been elucidated through 
investigations into inner ear development and the regeneration of their homologous 
organs in non-mammalian vertebrates. Yet much remains to be understood before we 













Figure 1.1| Overview of the inner ear. (A) The inner ear comprises six patches of 
sensory epithelia encased in a fluid-filled bony labyrinth and is located within the 
temporal bone. (B) The utricle and saccule lie orthogonal to each other, allowing for 
detection of linear acceleration in all directions. (C) The utricle and saccule have two 
polarities of hair cells (red) that reverse around the midline and are arrayed in a 
hexagonal pattern among supporting cells (green). The hair bundles are loaded by 
otoliths, crystals of calcium carbonate. (D) The ampullae of the three semi-circular 
canals bear hair cells (red) of a single polarity, and their hair bundles protrude into a 
gelatinous mass termed the cupula (yellow). (E) The organ of Corti lies along a tapered 
basal membrane that increases in width from the base of the cochlea to its apex. Inner 
hair cells (orange) transmit electrical signals to the central nervous system. Outer hair 
cells (red) play a role in amplifying and sharpening the signal. The organ of Corti has 
several types of supporting cells, defined by their location and function. Image in (A) 
was adapted from Retzius, G. Das Gehörorgan der Wirbelthiere. II. Das Gehörorgan der 





Section 1.1: The Mammalian Inner Ear  
The sensory epithelia of all mammalian hearing and vestibular organs derive from the 
otic placode—the anlagen of the inner ear—and thus share two cell types: supporting 
cells, which play a homeostatic and architectural role, and mechanosensitive hair cells, 
with their eponymous apical tufts of stereociliary bundles arranged in tightly packed 
rows of increasing height. Tip links, proteinaceous strings, connect the tips of adjacent 
stereocilia: at its upper edge, each tip link is attached through a series of 
transmembrane complexes to myosin motors, that mediate fast adaptation. At its lower 
end, a tip link is thought to be connected to ion channels, so thus stretching of the tip 
links opens the channels, depolarizing the cell (Fig. 1.2). The orientation of stereociliary 
rows, in conjunction with their tip link attachments, allows for their coordinated 
movement and directional specificity, for deflection in one direction opens ion channels, 
causing depolarization, and deflection in the opposite direction reduces the number of 
open channels, yielding hyperpolarization3.  
The sensory epithelia of the inner ear are arranged in distinct and precise  
geometrical patterns that are critical to their functions. All hair cells of the utricle and 
saccule, the organs responsible for the detection of linear acceleration, are either 
oriented towards or away from the line of reversal roughly at the midline, and are 
arrayed in a hexagonal pattern among supporting cells, which in these organs are 
considered a uniform type. The tips of the stereocilia are loaded by otoconia, clusters of 
calcium carbonate crystals that provide the mass for inertia-mediated activation (Fig. 







Figure 1.2| Hair bundles activate in response to unipolar movement. The stereocilia 
of hair cells are arranged in rows of increasing height, with tip links connecting the tops 
of each. The lower end of the tip links is embedded in ion channels, so when the 
bundles are deflected towards their tall edge the tip links stretch, opening the channels 
allowing divalent ions to flow through and depolarize the hair cells. Deflection in the 
opposite direction causes hyperpolarization, and deflection orthogonal to the apical 





Figure 1.2| Hair bundles activate in response to unipolar movement. The stereocilia 
of hair cells are arranged in rows of increasing height, with tip links connecting the tops 
of each. The lower end of the tip links is embedded in ion channels, so when the 
bundles are deflected towards their tall edge the tip links stretch, opening the channels 
llowing divalent ions to flow through and depolariz  the hair cells. Deflectio  in the 
opposite direction causes yperpolarization, and deflection orthogo al to the apical 
surface of the hair cell has no effect.  
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organs responsible for detecting rotational acceleration, are all oriented in a common 
direction. The long hair bundles are embedded in a gelatinous mass, called the cupula, 
that deflects upon inertial movement of the endolymph within the canals (Fig. 1.1D). 
Again the result is depolarization for motion in one direction and hyperpolarization in the 
other.4  
The cochlea, the organ that processes sound, has the most geometrically 
intricate organization. The sensory portion of the cochlea, known as the organ of Corti, 
lies upon a basilar membrane of tapering width from the base to the apex, a key 
component of its tonotopic gradient. The tunnel of Corti separates the two types of 
cochlear hair cells, all of which have their bundles’ short rows medially and tall rows 
laterally. These receptors lie among several classes of supporting cells, defined by their 
architectural as well as functional roles. Lateral to the tunnel are three parallel rows of 
outer hair cells, which are innervated primarily by efferent nerves, and play a role in 
amplification and frequency resolution through an active process. These cells display 
both depolarization-dependent cytoskeletal contraction and active motion of their 
bundles. In contrast, inner hair cells, medial to the tunnel, are innervated by afferent 







Section 1.2: Inner Ear Regeneration in Non-Mammalian Vertebrates 
Hair cell-based organs in several non-mammalian vertebrates regenerate throughout 
their lifetimes. Two models of note are the avian cochlea (basilar papilla) and the 
zebrafish lateral line. The latter, which comprises small patches of hair cells and 
supporting cells—the neuromasts—distributed longitudinally across the surface of the 
body, measures motion of the surrounding fluid for both during normal movement and in 
the presence of prey or predators. As in the mammalian utricle and saccule, equal 
numbers of hair cells face in the rostral and caudal directions, permitting bi-directional 
sensitivity. Studies of these organs in development and regeneration have shed much 
light on the high-level processes, as well as the common and the distinct pathways 
involved.  
The regenerative process in the avian cochlea involves two phases. An early 
wave of transdifferentiation, or direct conversion of supporting cells into hair cells, yields 
some new hair cells at the cost of supporting cells. To further enable regeneration, 
supporting cells adjacent to the site of damage undergo proliferation, yielding daughter 
cells that can either differentiate into hair cells or remain supporting cells, thus 
preserving the ratio of the cell types (Fig. 1.3A)6. After damage, supporting cells in the 
zebrafish neuromasts always undergo division before generating two new, oppositely 
oriented hair cells, thereby conserving the balance of vector sensitivity. Supporting cells 
also divide symmetrically to replenish their own number (Fig. 1.3B)7.  
From these studies and others, it has become clear that the two key processes 



















Figure 1.3| Hair cell regeneration in non-mammalian vertebrates. (A) In the avian 
cochlea (basilar papilla) hair cells regenerate throughout the organism’s lifespan. This 
process involves two main programs: (1) an early wave of transdifferentiation, direct 
conversion of adjacent supporting cells into hair cells; (2/3) proliferation of supporting 
cells, either symmetrically, replenishing the supporting cell population, or 
asymmetrically, yielding one daughter hair cell and one supporting cell. (B) The 
neuromast of zebrafish is surrounded by mantle cells (purple) and have hair cells (red) 
of two polarities arrayed amongst supporting cells (green). When hair cells die, a nearby 
supporting cell undergoes division, yielding two hair cells of opposite polarity. 




signaling paradigms underpin each. Both in development and regeneration, 
transdifferentiation is mediated primarily through canonical Notch signaling, an ancient 
short-range communication system. This process culminates in the activation of 
transcription factors that are necessary for hair cell differentiation, such as Atoh1 and 
Pou4F3. Several pathways have been implicated in control of supporting cell 
proliferation during regeneration, including Fgf, Wnt, Egf, and Igf signaling4,8.  
 
Section 1.3: Lack of Inner Ear Regeneration in Mammals 
In contrast to the lifelong regenerative capacity of non-mammalian vertebrates, 
functional hair cell regeneration is largely absent in mammals. In the adult mammalian 
utricle, it has been shown that a modest number of hair cells regenerates after total 
ablation. However, the new hair cells are predominantly the result of transdifferentiation, 
and it is unclear whether there is any significant functional recovery. Although this is a 
meager response, it lies in stark contrast to the total inability of the mammalian cochlea 
to yield any regenerative response4.  
 One typical explanation for why the mammalian cochlea does not regenerate is 
that, in contrast to its regenerative homologues, it has a drastically more complex 
architecture, thought to enable our higher range of frequency detection8. This reasoning 
applies less well to the vestibular organs, which are more similar in their organization to 
the avian cochlea and zebrafish neuromast. It has been argued that in the vestibular 
system, proliferation of supporting cells is impeded by rings of F-actin and E-cadherin 
junctions that accumulate around the cells as the organ ages9; this does not occur in the 
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regenerative systems. These observations might equally represent a down-stream 
effect due to a dearth of proliferation, however and not a primary cause. No functional 
evidence has been generated in support of this hypothesis.  
 More is known about the molecular roadblocks preventing regeneration. In the 
cochlea, transdifferentiation is completely absent after damage. In the regenerative 
homologues, it is known that Notch-mediated signaling plays a key role. However, in the 
adult mammalian cochlea, Notch-responsive genes are expressed at very low levels, 
and although some components are upregulated after damage, Notch inhibition in this 
context fails to drive significant generation of new hair cells. It is unknown how the 
Notch responsiveness of these supporting cells is kept low8,10. In the adult mammalian 
utricle new hair cells can arise by transdifferentiation throughout an organism’s lifespan, 
although it is unclear how robust the physiological recovery is. In accord with the 
utricle’s slightly stronger regenerative capacity, activation of Notch signaling in 
supporting cells after hair cell ablation upregulates Atoh1 expression, an early marker of 
hair cell differentiation, and a subset of the cells express Myo7a, a marker of mature 
hair cells4.  
 Because it is thought that cell division is a key limiting step in the regenerative 
response, anti-proliferative programs have also been an area of intense focus. Wnt 
signaling has been shown to drive supporting cell proliferation in both the developing 
utricle and cochlea.  However, both organs become refractory to Wnt activation as they 
age. Several of the cyclin-dependent kinase inhibitors (CDKIs) have also been shown to 
play critical roles in maintaining the post-mitotic status of the cochlea: p19Ink4d, 
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p21Cip1, p27Kip1, Rb1, and Rbl2. In the utricle, Rb1 has been demonstrated to impede 
proliferation, but p19Ink4d and p21Cip1 appear to play no role4,8,10.  
 
Section 1.4: Approaches to Inducing Inner Ear Regeneration  
The insights from the investigations highlighted above have directed researchers into 
two main avenues of inducing hair cell regeneration. The first, and more thoroughly 
studied goal, is that of inducing supporting cell transdifferentiation. Although much more 
remains to be investigated, several approaches have demonstrated its potential, as well 
as its limitations. The second goal, driving supporting cell proliferation, is thought to be a 
key limitation on regeneration, given the natural evidence of its import in bird and 
zebrafish homologues, as well as the poor results to date of using only 
transdifferenation to drive hair cell regeneration in mammalian systems.   
 Because hair cell differentiation across these many systems, during both 
development and regeneration, is Notch-mediated, many groups have utilized gamma-
secretase inhibitors in attempts to augment this process in the adult mammalian 
systems. Within a few days after birth, the cochlea down-regulates its Notch ligands and 
becomes insensitive to inhibition. However, although there is not complete consensus, 
some groups report that after damage, the cochlea can upregulate some of the Notch 
program. In support of this hypothesis, gamma-secretase inhibition applied to noise-
damaged mice increased the number of outer hair cells, but only at the base of the 
cochlea. Although there was a notable, but small, physiological recovery at the lowest 
frequencies, the overall recovery was minimal at best. Application of a different gamma-
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secretase inhibitor after damage led to ectopic hair cells in guinea pigs. No significant 
physiological recovery was appreciated10.  
 Because Notch signaling is still active in the adult vestibular system, the utricle 
can form more hair cells after gamma-secretase treatment in vitro. The preponderance 
of this work has been done in explant culture systems and varies in details of the 
results: how many new hair cells, the extent of their maturation, and what region of the 
utricle are new hair cells found. Moreover, no one has yet demonstrated physiological 
recovery in vivo with this approach4.  
 The other major approach taken for inducing transdifferentiation is to over-
express Atoh1, a transcription factor necessary for—and somewhat sufficient— for the 
induction of hair cell formation. In the utricle, virally mediated and transgenic 
approaches have been employed, but yielded different results. Adenovirus-mediated 
gene delivery improved hair cell regeneration in damaged vestibular organs from adult 
rodents; however, physiological recovery was small to absent. The transgenic approach 
failed to drive formation of any new hair cells in the adult. In the cochlea, Atoh1 over-
expression, either virally or through transgenics, failed to yield new hair cells10.  
 Several programs, including Wnt signaling and numerous growth factors, have 
been shown to augment proliferation during development, but sensitivity to these 
perturbations is lost only a few days after birth in both the utricle and the cochlea4,10. In 
the utricle, a more drastic measure, over expressing the oncogene N-Myc, did yield 
supporting cell proliferation in adult utricle explants in vitro, but all of the cells failed to 
progress through G2 or underwent apoptosis after completion of the cell cycle11. Our 
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group found that the pioneer transcription factors Sox4 and Sox11 are key in the 
proliferation of utricle supporting cell during development; moreover, virally mediated 
over-expression in adult explants induced supporting cell proliferation, and a subset of 
the resultant cells then differentiated into hair cells12. No approaches have been 
demonstrated to induce supporting cell proliferation in the cochlea.  
 
Section 1.5: Hippo-Yap Signaling 
A former member of our group, Dr. Ksenia Gnedeva, demonstrated that the Hippo 
pathway limits the size of the developing murine utricle, and that the pathway’s down-
stream target, the Yap-Tead complex is active during—and necessary for—proliferative 
regeneration in the neonatal utricle13. These observations suggested that activation of 
Yap signaling could engender supporting-cell proliferation in adult tissue.  
In view of its fundamental roles in development, proliferation, stem-cell 
maintenance, and de-differentiation, Hippo signaling is an inviting target for driving 
regeneration14,15. The canonical Hippo pathway is an ancient and highly conserved 
signal-transduction cascade that comprises two pairs of core kinases. When proliferation 
is inappropriate, Mst1 and Mst2 phosphorylate Lats1 and Lats2; these proteins in turn 
phosphorylate the transcriptional co-activator Yap and its homolog Taz, which as a result 
are sequestered and degraded in the cytoplasm. When the pathway is inactive, Yap 
enters the nucleus, interacts with transcription factors of the Tead family, and initiates cell 
division16. Yap signaling integrates a variety of information from the cellular environment, 
including biomechanical cues, cell adhesion, cell density, cell polarity, metabolic 
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challenges, and signals such as Notch, Wnt, and several GPCR-mediated pathways. The 
Hippo cascade is the conduit through which much, but not all, of this information is 
integrated into a decision regarding Yap activation17 (Fig. 1.4).  
Yap activity has been shown to play a role in the mammalian organs which can 
regenerate, such as the liver, lung, intestine, and skin14. Furthermore, increasing Yap 
activation in these contexts augments the regenerative response in vivo. Of greater 
interest, Yap activation has also been shown to drive regeneration in non-mitotic tissues 
such as the heart and retina. After induction of myocardial infarction in adult mice, 
treatment with agrin, a secreted protein that activates Yap specifically in that context 
through the Dag1 receptor, can cause proliferation of adult mouse cardiomyocytes in vivo. 
One month later the ejection fraction of treated mice was identical to that of undamaged 
mice18. In retinal tissue, transgenic overexpression of a constitutively active form of Yap 
in Müller cells, precursors of photoreceptors, drives cell cycle re-entry, a key missing step 
in mammalian retinal regeneration19,20. 
Despite the evidence that Yap reactivation offers a uniquely powerful approach for 
tissue regeneration, the techniques involved are cumbersome, indirect, or context-
specific21. Transgenic manipulation, viral induction, and GPCR-mediated Yap activation 
lack translational value, so due to these shortcomings of available tools, we conducted a 
screen for small-molecule activators of Yap. With such a compound, we hoped to test our 
original hypothesis that Yap activation in supporting cells of the adult utricle would foster 




















Figure 1.4| The Hippo Pathway. (A) The core of the Hippo pathway comprises two 
pairs of kinases, MST1/2 and LATS1/2, each with co-activators, Sav1 and Mob1 
respectively. Despite the relative simplicity of the cascade, there is no specific ligand 
and receptor, but instead numerous inputs (“Hippo Regulators”) impinge upon the 
cascade at various entry points, yielding an integrative decision regarding Yap 
activation. When active, the cascade culminates in the phosphorylation of Yap at 
multiple sites, yielding sequestration and degradation of the protein. When the cascade 
is inactive, Yap remains unmodified and is free to translocate to the nucleus, where it 
binds primarily to members of the Tead family, driving its transcriptomic programs. 
Small molecules known to modify the Hippo pathway, and their modes of action, are 
















































Section 1.6: Identification of Activators of Yap Signaling  
In some monolayer epithelial cultures, increased cell density leads to cytoplasmic 
retention and degradation of Yap protein, a process reminiscent of the molecular 
mechanism downstream of Hippo-driven growth restriction during normal 
development22,23,24. To seek inhibitors of this process, former members of our group 
designed a high-throughput phenotypic screen for compounds that promote nuclear Yap 
translocation in confluent human cell cultures. After testing three lines, they chose 
MCF 10A mammary epithelial cells, which demonstrated robust negative correlation 
between cellular confluence and the fraction of cells with nuclear Yap. 
 For the small-molecule screen, MCF 10A cells were seeded to achieve dense cultures 
in 384-well plates. A single compound was deposited in each well at a concentration of 
10 µM. Every plate also included a positive control, sub-confluent cells, and a negative 
control, densely cultured cells, both exposed to dimethyl sulfoxide (DMSO) at a 
concentration equivalent to that in which the compounds were applied. After 24 hr 
incubation, the investigators determined the fraction of the cells with nuclear Yap and 
compared that value to the median negative-control value. They also scored the total 
number of cells in each well and eliminated toxic substances that decreased the number 
by more than one standard deviation in comparison to the dense control cultures. 
Nontoxic compounds that increased nuclear Yap by more than one standard deviation in 
comparison to the negative control were scored as hits. Owing to the robustness of 
contact inhibition in the dense cell cultures, only six of the 140,238 compounds screened 





Animal care and strains 
Experiments were conducted in accordance with the policies of the Institutional Animal 
Care and Use Committees of The Rockefeller University, the University of Southern 
California, and the Weizmann Institute of Science. 
Swiss Webster mice were obtained from Charles River Laboratories. Sox2-
CreER, aMHC-Cre, and ROSA26-tdTomato mice were obtained from the Jackson 
laboratory. Yapfl/fl were provided by Dr. Martin, Baylor College of Medicine.  
 
Chemical libraries 
A total of 140,238 different compounds from a library at The Rockefeller University 
High-Throughput and Spectroscopy Resource Center were chosen by a quantitative 
estimate of drug-likeness score26. The compounds originated in the following 
commercially available libraries: ChemDiv (San Diego, CA), Enamine (Monmouth 
Junction, NJ), BioFocus (Charles River, Wilmington, MA), ChemBridge (San Diego, 
CA), Specs (Zoetermeer, The Netherlands), Life Chemicals (Niagara, Canada), and 
AMRI (Albany, NY). Compound stocks were stored in 384-well polypropylene plates at a 




High-throughput screen for small-molecule activators of nuclear Yap 
Three human epithelial cell lines, one human embryonic kidney 293 line (HEK293T), 
and two human mammary gland epithelia lines (MDA-MB and MCF 10A), were tested 
for the screen. Of the three lines, only MCF 10A cells display a reproducible correlation 
between the number of cells seeded and the number of cells adhered after 24h in 
culture and thus were selected for the screen. 
MCF 10A cells (ATCC CRL-10317) were cultured in a medium comprising 
DMEM/F12, 5 % horse serum (Invitrogen 16050-122), 20 ng/L epidermal growth factor 
(Millipore GF155), 0.5 mg/L hydrocortisone (Sigma H-0888), 100 ng/L cholera toxin 
(Sigma C-8052), 10 mg/L insulin (Sigma I-1882), and antibiotic-antimycotic solution. 
Cell cultures reached 100 % confluence at an approximate density of 3·105 cells per 
square millimeter.  
For the small-molecule screen, chemical-library plates were thawed at room 
temperature and 0.1 μL of each compound was placed in a well of a 384-well assay 
plates (Greiner Bio-One) containing 10 μL of MCF 10A culture medium (PerkinElmer 
Janus with Nanohead). MCF 10A cells were then plated in 40 μL of MCF 10A culture 
medium to achieve a final concentration of 10 µM for each compound and 0.25 % 
(vol/vol; 35 mM) dimethyl sulfoxide. Negative (100 % confluent) and positive (25 % 
confluent) control wells included an identical concentration of the DMSO vehicle. 
After 24 hr incubation, the cells were fixed, washed thrice in PBS, and 
immunolabeled for Yap. The nuclei were stained with 3 mM 4,6-diamidino-
2-phenylindole dihydrochloride (DAPI). 10X objective lens on the ImageXpress XLS 
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wide-field Micro reader (Molecular Devices, Sunnyvale, CA) with MetaXpress software 
(Molecular Devices) were use to automatically image the plates. Using an empty plate 
to avoid out-of-focus images, we configured a laser-based autofocus routine for 
automatic well-bottom detection. We imaged DAPI and Yap conjugated to Alexa Fluor 
488 with filter cubes for respectively DAPI (excitation, 350-400 nm; emission 
415-480 nm) and FITC (excitation, 460-505 nm; emission, 510-565 nm). The acquisition 
system was configured to image one site per well. After the fluorescence of DAPI had 
been used to set the image-based autofocus, the exposure time for each fluorophore 
was determined with a negative-control well in which the fluorescence signal was set to 
75 % of the camera’s maximal intensity. 
An image-segmentation application from MetaXpress software was used to 
automatically analyze the images. The number of cells was estimated by selecting an 
average size and intensity level above the local background in the DAPI channel.  
A built-in translocation module that measured the intensity movement from one 
compartment to another was configured to determine the nuclear or cytoplasmic status 
of the Yap. These measurements were acquired first for the positive and negative 
control wells to determine an arbitrary threshold for the intensity ratio that characterized 
nuclear translocation versus cytoplasmic retardation of Yap. The same threshold was 
then applied to each well treated with a small-molecule to identify the substances that 
increased the number of cells with nuclear Yap without affecting cell survival. Positive 
controls were not used to normalize data, but to confirm whether the cells were healthy 
and behaving as expected. 
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Images were stored in the MDCStore database and analyzed using MetaXpress 
software (Molecular Devices). Output data were uploaded and analyzed using the CDD 
Vault from Collaborative Drug Discovery (Burlingame, CA). 
The compounds showing over 10 % Yap nuclear translocation and over 5,000 
cells per field were selected and the corresponding images were checked to verify the 
phenotype. To determine half-maximal inhibitory concentrations, the selected 
compounds were re-tested in concentration-response experiments by serially diluting by 
half for a total of ten dilutions to achieve assay concentrations ranging from 20 µM to 
0.03 µM. IC50s values were calculated by CDD software. Six compounds were 
confirmed in this secondary screen.  
 
Small-molecule Lats inhibitor 
The compound N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-
3-carboxamide (CAS number 1424635-83-5), of relative molecular mass 334.4 Da and 
herein termed TRULI, was obtained from Enamine LLC (Monmouth Junction, NJ; 
catalog number Z730688380). 
 
Dissection and culture of inner-ear sensory epithelia 
Internal ears were dissected from mice euthanized with fluothane and placed into ice-
cold Hank’s balanced salt solution (HBSS; Gibco14025-092)12. 
Unless indicated otherwise, explanted cultures of the utricle and cochlea were 
maintained in an incubator at 37 ˚C in the presence of 5 % CO2 and 95 % O2. The 
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complete growth medium comprised Dulbecco's modified Eagle medium with nutrient 
mixture F-12 (DMEM/F12) supplemented with 33 mM D-glucose (Sigma G8644), 
19 mM NaHCO3 (Sigma S8761), 15 mM HEPES (Sigma H0887), 1 mM glutamine 
(Sigma G8540), 5 mM nicotinamide (Sigma N0636), 40 µg/L epidermal growth factor 
(Sigma E9644), 20 µg/L fibroblast growth factor (Sigma F5392), insulin-transferrin-
selenite solution (Sigma 11074547001), and antibiotic-antimycotic solution (Gibco 
15240062). 
For proliferation assays, utricles were cultured with 10 µM 5-ethynyl-
2¢-deoxyuridine (EdU) that was detected with click chemistry (Click-iT EdU imaging kit, 
Thermo C10340). 
 
Culture of epithelial cells 
MCF 10A cells were cultured as described above. HEK293A cells were maintained in 
DMEM (Gibco 11965-092), 10 % fetal bovine serum (Sigma F2442), and antibiotic-
antimycotic solution. All cells were incubated at 37 ˚C in the presence of 5 % CO2 and 
95 % O2. 
 
Culture of primary cardiomyocytes 
Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by 
intercrossing aMHC-cre mice27, which exhibit highly efficiency recombination in 
cardiomyocytes, with ROSA26-tdTomato mice28 that require Cre-mediated 
recombination for expression. Both lines were maintained on a C57BL/6 background. 
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Neonatal primary cardiac cultures were isolated from P0 (first postnatal day) 
pups with a neonatal dissociation kit (Miltenyi Biotec,130-098-373) and homogenizer 
(gentleMACS). Cardiac cultures were seeded in gelatin-coated wells coated with 0.1 % 
gelatin (G1393, Sigma) in DMEM/F12 medium supplemented with 1% L-glutamine, 1 % 
sodium pyruvate, 1 % nonessential amino acids, 1 % penicillin-streptomycin solution, 
5 % horse serum, and 10 % fetal bovine serum. After culture in 5 % CO2 for 24 hr at 
37 ˚C, the medium was replaced for an additional 72 hr with bovine serum-free medium 
containing 0.1 % (vol/vol) DMSO and, for experimental samples, 20 µM TRULI. 
 
Culture of human pluripotent stem cells and retinal organoid 
The WTC-11 line of induced pluripotent stem cells (Coriell Institute for Medical 
Research, Camden, NJ) was maintained using standard methods. Human retinal 
organoids were produced from these cells29. In three independent proliferation assays, 
five organoids per experimental condition were sampled after 225-280 d in culture. The 
organoids used in the immunoiblot analysis were cultured for 160-178 d. 
 
Immunohistochemistry of murine inner-ear sensory epithelia 
Utricles were fixed in 4 % formaldehyde (Thermo 28906) for 1 hr at room temperature 
and then blocked for 2 hr at room temperature with 3 % bovine serum albumin (BSA; 
Jackson AB 2336846), 3 % normal donkey serum (Sigma-Aldrich D9663), and 0.3 % 
Triton X-100 (Sigma 93443), in Tris-buffered saline solution (Thermo 28358). 
 25 
The primary antisera—goat anti-Sox2 (R&D AF2018), rabbit anti-myosin 7A 
(Proteus 25-6790), mouse anti-Yap (SC-101199), rabbit anti-Sall2 (HPA004162), and 
mouse anti-Pou4F3 (SC-81980)—were reconstituted in blocking solution and applied 
overnight at 4 ˚C. Samples were washed with phosphate-buffered saline solution 
supplemented with 0.1 % Tween 20 (Sigma-Aldrich), after which Alexa Fluor-labeled 
secondary antisera (Life Technologies) were applied in the same solution for 1 hr at 
room temperature. Nuclei were stained with 3 mM DAPI. 
 
Immunofluorescence assays for cardiomyocytes 
Cells were fixed in 4 % formaldehyde for 10 min with shaking at room temperature, 
permeabilized for 5 min with 0.5 % Triton X-100 in PBS, and blocked for 1 hr at room 
temperature with 5 % BSA in PBS containing 0.1% Triton X-100. The cells were labeled 
overnight at 4 ˚C with the primary antibodies anti-Ki67 (1:200, 275R, Cell Marque) and 
anti-phosphorylated histone 3 (1:200, 9701, Cell Signaling) for. After three washes with 
PBS, samples were labeled for 1 hr at room temperature with fluorescent secondary 
antibodies (Abcam) followed by 10 min of DAPI staining for nuclear visualization. After 
three washes in PBS, cells were imaged with a Nikon Eclipse Ti2 microscope. 
 
Immunofluorescence imaging of retinal organoids 
Fresh frozen sections were permeabilized and blocked in a humidified chamber for 1 hr 
at room temperature with 3 % horse serum in PBS with 0.3 % Triton X-100. The slides 
were exposed for 2 hr to primary antibodies diluted in the same solution. Anti-Sox-9 
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(1:100, Rb Cell Signaling 82630) was used to mark Müller cells. Slides were washed 
three times with PBS. Secondary antisera (Alexa-Fluor 488 and 647) diluted 1:10,000 in 
the serum solution were added for 1 hr at room temperature followed by two washes 
with PBS. Labeling for 30 min at room temperature (Apply Click-iT Invitrogen Alexa 
Fluor 555 C10338) was followed by a wash with PBS. After incubation with DAPI 
(1:10,000 in PBS) for 5 min and the application of mounting solution, sections were 
imaged by confocal microscopy with a Zeiss LSM 700 system with a 20X/0.8 NA 
objective lens with a pinhole size set at the first Airy disc. 
 
Protein immunoblotting and quantification 
MCF 10A, HEK293 cells, retinal organoids, and utricles were lysed on ice in 
radioimmunoprecipitation assay buffer solution (RIPA; BP-115-5x) with protease 
inhibitors (Halt Protease Inhibitor Cocktail, Thermo 87786). Utricles were additionally 
sonicated thrice at low power for 10 s, with breaks of 20 s with the samples kept on ice 
between sonications  After lysates had been scraped and centrifuged at 10,000 RPM for 
10 min at 4 ˚C, the supernatants were immediately subjected to electrophoresis or 
stored at -80 ˚C.  
A standard immunoblotting protocol was used with the following specifications. A 
4-12 % bis-tris gel (Thermo NP0322) was used to resolve the proteins in 5 mg of each 
sample. The proteins were transferred to a nitrocellulose membrane (BioRad 1704156) 
and blocked for 1 hr at room temperature (Rockland MB-070). After primary antibodies 
had been reconstituted in the same solution, the membrane was incubated overnight at 
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4 ˚C. After three 5 min washes at room temperature in tris-buffered saline solution with 
0.05 % Tween 20, a secondary antibody conjugated to horseradish peroxidase 
(Millipore) was applied in the same solution for 1 hr at room temperature before activity 
was detected (SuperSignal West Pico PLUS, Thermo 34580). Images were acquired 
with an iBrightFL1000 system.  
We used at a dilution of 1:1000 primary antibodies directed against Yap 
(sc-101199), phospho-Yap S127 (CST 4911), Lats1 and Lats2 (Abcam, ab70565), 
phospho-Lats1 S909 (CST 9157), Mst1 (CST 3682), Mob1 (CST 13730), 
phospho-Mob1 T35 (CST 8699), tubulin (Sigma T6793), and GAPDH(Abcam ab8245). 
Cultured cardiomyocytes were lysed using RIPA supplemented with protease 
and phosphatase inhibitors (1:100, Sigma). Lysates were prepared and 30 µg protein of 
each sample was fractionated by gel electrophoresis in tris-glycine acrylamide gels, and 
subsequently transferred to a PVDF membrane. Following 1 hr blocking at room 
temperature, membranes were incubated with the following antibodies against 
phospho-Yap at s112 (1:1000, 13008, cell signaling), Yap (1:2000, NB110-58358, 
Novus) and Rabbit anti GAPDH (1:8000, PLA0125, Sigma) for 1 hr at room 
temperature. Following two washes in tris-buffered saline solution containing 0.1 % 
Tween 20, membranes were incubated with horseradish peroxidase anti-rabbit or 
secondary antibodies (Jackson). The signal was detected by super-signal west pico 
plus chemiluminescence kit (34580, Thermo-Fisher). 
Immunoblots were quantified through measurement of band intensity with Fiji30. 
The final value of each band’s intensity was normalized by the sum of all the bands’ 
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intensities. Significances from one-sided Student’s t-tests are denoted as follows: *, 
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
 
Imaging of Yap nuclearization and quantification of proliferation  
Confocal imaging was conducted with a confocal microscope enhanced with structured 
illumination (VT-iSIM, VisiTech International Ltd.). 
For quantification of Yap nuclearization, for each condition two fields of 
supporting cells were imaged at 60X from two utricles. Using CellProlifer31, we masked 
Sall2-positive nuclei and measured the intensity of their labeling. The same mask was 
then applied to the Yap channel and the intensity of labeling was measured. The ratio of 
the Yap to the Sall2 intensity was calculated for each condition in 680 cells after TRULI 
treatment and 570 cells for DMSO controls. 
For quantifying the proliferation of supporting cells, we imaged utricles at 60X, 
then assembled the images into a composite tiling (Grid Collection Stitching, Fiji). The 
maximal values in z-stacks were projected to display the entire supporting-cell layer of 
the sensory epithelium, excluding connective tissue and the surrounding epithelium. 
Using CellProlifer31, we counted the number of EdU-positive nuclei. Alternatively, EdU- 
and Sox2- doubly positive nuclei were counted using Multi-point Tool in ImageJ. 
Images acquired from neonatal cardiac cultures were analyzed using ImageJ 
software by thresholding for cardiomyocytes according to endogenous tdTomato 
fluorescence. Thresholded figures were carefully and manually separated by fine lines 
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to de-cluster cells in case they touch, basing on original images, following by 
measurements of area and solidity.  
Images acquired from retina organoids were analyzed with CellProfiler31. Masks were 
created for all the Sox9-positive nuclei, and the percentage of EdU- and Sox9-positive 
nuclei were counted.  
 
In vitro kinase assay 
The in vitro kinase assay (HTRF KinEASE-STK S1, CisBio 62ST1PEB) was optimized 
to the linear reaction range of the enzymes Lats1 (Carna 01-123) and Lats2 
(Carna 01-124). Reactions were conducted with 10 µM STK1 substrate and 10 µM ATP, 
unless otherwise indicated. For the ATP-shift assay, ATP was also used at 
concentrations of 50 µM and 250 µM. Lats1 was employed at a concentration of 200 
pg/µL and Lats2 at 50 pg/µL, unless otherwise indicated. For the assay in which 
Michaelis-Menten constants for ATP were determined, each enzyme was at a 
concentration of 62.5 pg/uL, and Lats1 ran for 30 min, and the Lats2 ran for 20 min, all 
at room temperature. The DMSO concentration was maintained at 0.5 % (vol/vol) 
throughout all experiments, and a Janus 384 MDT (PerkinElmer) equipped with a 50 nL 
Pintool (V&P Scientific, Inc.) was used to add the compounds dissolved in DMSO to the 
reaction. The enzyme, substrate, ATP, and TRULI were combined in a low-volume 384-
well plate and shaken for 50 min at room temperature, unless otherwise indicated. The 
reaction was stopped by adding the detection reagents, which were prepared at an 8:1 
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biotin:streptavidin ratio, and shaken for 60 min at room temperature. All reactions were 
conducted in triplicate and a Synergy NEO (Biotek) was used to detect the signal. 
 
Cellular kinase assay 
HEK293A cells were plated overnight in 96-well culture plates at a density of 50,000 
cells per well in the medium described above. To start the assay, new serum-free 
medium with various concentrations of the compound was added to the cells, which 
were then incubated for 30 min at 37 ˚C. The DMSO concentration was kept at 0.1 % 
(vol/vol), and all experiments were performed in triplicate. 
Total Yap and phospho-Yap were detected according to the two-plate protocol 
for adherent cells (Total Yap Cellular Kit, Cisbio 64YATPEG; phospho-Yap [Ser127] 













Explant Studies on Screen Hits 
 
Having found the six validated hits in the primary screen, we turned to our model 
system of interest, adult murine utricle explants, to test our original hypothesis that Yap 
activation could drive supporting cell proliferation. I assayed the hits at various 
concentrations and times, using immunohistochemistry to assess Yap activation and 
ensuing proliferation. During our screen XMU-MP-1, an inhibitor of the Mst1/2 kinases, 
was published, so we included it in our analysis as well32. Ultimately, of the seven 
compounds tested, only one, RU-5757, demonstrated all the characteristics of interest.  
 
Section 3.1: Adult Murine Utricle Explants  
RU-5757, or N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, 
drove robust Yap nuclear translocation after 24 hr of treatment at a concentration of 
10 µM (Fig. 3.1) and caused a striking reduction in the level of Yap phosphorylation. After 
5 d of treatment, this substance evoked robust re-entry into the cell cycle of adult utricular 
supporting cells (Fig. 3.2). For the sake of brevity we term this substance "TRULI."  
Although XMU-MP-1 modestly reduced the amount of phospho-Yap, it decreased 
the total Yap by a greater amount so that the ratio of phospho-Yap:total Yap actually 























Figure 3.1| TRULI drives Yap nuclearization. (A) Immunohistochemistry demonstrates 
that TRULI exposure drives Yap, yellow, into the nuclei of utricular supporting cells. 
Sall2, green, is a nuclear marker of supporting cells (B) The nuclear localization of Yap 
is quantified as a ratio to the constitutively expressed protein Sall2 (p < 0.0001 by an 


























































Figure 3.2| TRULI drives supporting cell proliferation. (A) In vitro exposure to TRULI 
for 5 d elicits proliferation of supporting cells, as measured by the incorporation of EdU. 
Verteporfin, an inhibitor of the Yap-Tead interaction, drastically reduces this effect. 
(B) The number of EdU-positive cells per utricle increases with TRULI (p = 0.021 by an 
unpaired, one-tailed t-test, control n = 2, TRULI n = 3), but the effect is blocked by 






























































Figure 3.3| XMU-MP-1 fails to activate Yap. (A) Six utricles per condition were treated 
for 24 hr with 10 µM TRULI or XMU-MP-1 to assess effects on the amount of 
phospho-Yap by comparison to control conditions. (B) Quantification of band-intensity 
ratios for phospho-Yap and total Yap in the immunoblot of panel A shows that 




















































Figure 3.4| XMU-MP-1 fails to drive supporting cell proliferation. When adult mouse 
utricles were explanted and cultured with EdU (white) and either TRULI or varying 
concentrations of XMU-MP-1 for 5 DIV, the latter caused no increase in proliferation. 










Section 3.2: Yap Dependence of TRULI-Mediated Proliferation  
To test whether the proliferative effect of TRULI is exerted through Yap, we co-
treated explants with TRULI and 5 µM verteporfin, an inhibitor of the interaction between 
Yap or Taz and Tead transcription factors33. Consistent with the hypothesis, co-treatment 
with verteporfin precluded a proliferative response (Fig. 3.2) To confirm these results, a 
collaborator at USC, Ksenia Gnedeva, used SOX2-CreER and Yapfl/fl mice to generate 
inducible conditional-knockout animals deficient for the protein in the sensory organs of 
the inner ear34,35. Owing to the extensive lifetime of Yap protein36, Cre-mediated 
recombination was induced either 7 d or 14 d prior to utricular explantation and culture. 
In the utricles isolated from Yapfl/fl littermate mice lacking Cre recombinase, treatment 
with TRULI elicited robust proliferation of supporting cells25. In contrast, in utricles 













Elucidation of TRULI’s Mechanism  
 
Having demonstrated that TRULI drives Yap-mediated supporting cell proliferation in 
the adult murine utricle, we aimed to determine its mechanism of action.  To this end, 
we employed two cell line models with distinct methods of activating Hippo signaling. 
Within these contexts we applied TRULI and found that in both, it interferes with the 
ability of Lats1/2 to phosphorylate Yap, either directly or indirectly. The structure of 
TRULI contains a hinge-binding motif indicative of ATP-pocket-binding mechanism of 
inhibition. To test this hypothesis, we developed an in vitro kinase assay (IVKA) to 
characterize the inhibitory potency of TRULI on Lats1/2. Together, these experiments 
demonstrate that TRULI is an ATP-competitive inhibitor of the Lats1/2 kinases.  
 
Section 4.1: Initial Assessment of TRULI Mechanism 
After treatment of confluent MCF10a cells with 10 μM of TRULI for 24 hr, protein blotting 
revealed that the Hippo signaling cascade was intact through the phosphorylation of the 
activation loops of Lats1 (S909) and Lats2 (S872) (Fig. 4.1). However, the 
phosphorylation of Yap at residue S127 was decreased, suggesting that TRULI is—
directly or indirectly—an inhibitor of Lats kinases. 
To confirm this inference we turned to HEK293A cells, which activate Lats kinases 





Figure 4.1| TRULI prevents Lats-mediated Yap phosphorylation in confluent 
MCF10a cells.  Protein immunoblotting discloses that 24hr treatment of MCF 10A cells 
with TRULI leaves Hippo signaling intact through the activation of Lats kinases, but that 







































deprivation37,38. We pre-treated 80 % confluent HEK293A cells with 10 μM TRULI for 1 hr, 
followed by 30 min of serum starvation. In control cultures, starvation elicited robust 
phosphorylation of Lats1 at S909 and the consequent phosphorylation of Yap at S127 
(Fig. 4.2). In cultures pre-treated with TRULI, however, serum starvation failed to evoke 
phosphorylation of Yap despite the activation of Lats1. Even under treated, serum-fed 
conditions, phospho-Yap levels were below those of serum-fed control cells. Negative-
feedback regulation in response to elevated Yap activity might explain why the amount of 
Lats1 S909 was enhanced in the treated, serum-fed condition39. These results together 
confirmed that TRULI interferes with the ability of Lats kinases to phosphorylate Yap. 
 
Section 4.2: ATP-competitive, Direct Inhibition of Lats1/2  
The structure of TRULI includes a 7-azaindole moiety characteristic of the hinge-binding 
motifs of ATP-competitive kinase inhibitors (Fig. 4.3A) Because there are no available 
crystal structures of the Lats kinases, collaborators at the Tri-Institutional Therapeutics 
Discovery Institute created a homology model from the crystal structure of the ATP pocket 
of similar kinase ROCK1 bound to a small-molecule inhibitor containing a 7-azaindole 
moiety. A putative structure of the complex between Lats1 and TRULI was then generated 
by molecular docking25. Because the predicted protein-ligand contact residues of Lats1 
and Lats2 are almost completely conserved, the model suggests that TRULI can bind 





Figure 4.2| TRULI prevents Lats-mediated Yap phosphorylation in serum-starved 
HEK293A cells. Serum starvation of HEK293A cells in the presence of TRULI also 

























































Figure 4.3| TRULI is an ATP-competitive inhibitor of the Lats kinases. (A) TRULI 
comprises a thiazolimine backbone with two substituents: a benzyl group and a 
7-azaindole hinge-binding motif. (B) An in vitro assay of Lats1 kinase activity shows that 
the IC50 for TRULI increases with the ATP concentration, from 0.2 nM at 10 µM, to 4.3 nM 
at 50 µM, and to 80 nM at 250 µM, demonstrating that the compound is an ATP-
competitive inhibitor. (C) The half-maximal inhibitory concentration of TRULI against 




















































To test our speculations about the mechanism of TRULI inhibition, we optimized 
an in vitro kinase assay with truncated forms of Lats1 (residues 589-1130) and Lats2 
(residues 553-1088) that include primarily the kinase domains. As a substrate we 
employed the peptide STK1, which is known to be phosphorylated by these enzymes40. 
Because we hypothesized TRULI was ATP-competitive, we first determined the 
Michaelis-Menten constants of Lats1 and Lats2 for ATP to be near 10 µM for both 
enzymes25; we then conducted the initial in vitro kinase assays at that concentration. 
Under these conditions, we found that TRULI directly inhibits both Lats1 and Lats2 with 
a half-maximal inhibitory concentration (IC50) of 0.2 nM (Fig. 4.3B,C). In view of these 
results, we named the compound TRULI: “The Rockefeller University Lats inhibitor." In 
support of our hypothesis, increases in ATP concentrations yielded positive shifts in the 













The Effects of TRULI in Other Contexts 
 
Because the regenerative effects of activating Yap in organs such as the retina and heart 
have been characterized extensively18,19,41,42, we investigated whether TRULI treatment 
is effective in eliciting cellular proliferation in these organs. The results demonstrate that 
TRULI can faithfully reproduce prior results, otherwise derived with cumbersome 
techniques, and thus TRULI is likely to be a widely applicable approach for researchers 
in various fields. Moreover, derivatives of TRULI, which are optimized for in vivo 
application, may offer therapeutic modalities in various pathologies.  
 
Section 5.1: Cardiomyocyte Data 
The proliferative capacity of cardiomyocytes in culture and the capacity of the heart 
to regenerate decline sharply after birth41. To ascertain whether TRULI activates Yap and 
induces regeneration, collaborators at Weizmann Institute exposed P0 murine 
cardiomyocytes to TRULI for 3 d. In control cultures, protein blotting revealed high levels 
of phospho-Yap indicative of Hippo activity. TRULI treatment reduced the proportion of 
phosphorylated Yap and induced cardiomyocyte proliferation, as demonstrated by a 
significant increase in the percentage of cells positive for the markers Ki67 ad 
phosphorylated histone H3 (Fig. 5.1A-E). Moreover, treated cells developed cytoskeletal 
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rearrangements and protrusions and decreased in size, phenotypes consistent with 
de-differentiation (Fig. 5.1F,G)43. 
Section 5.2: Retina Organoid Data 
Yap activation can induce retinal regeneration by increasing the proliferation of 
Müller glial cells, progenitors with a capacity to differentiate into photoreceptors and 
neurons19,20. To test whether TRULI induces the proliferation of Müller glia, collaborators 
at Children’s Hospital of L.A. used retinal organoids derived from human induced 
pluripotent stem cells. Western blotting demonstrated loss of Yap phosphorylation in 24 
hr TRULI-treated organoids. And while Müller cells remained largely quiescent in control 
cultures, in organoids treated for 5 d with 10 µM TRULI, Müller cells exhibited a robust 












Figure 5.1| TRULI activates Yap in neonatal murine cardiomyocytes, driving 
proliferation. (A) A protein immunoblot indicates that TRULI decreases the 
phosphorylation of Yap in neonatal cardiomyocytes in vitro. (B) Quantification of the data 
in panel A shows the significance of the effect (p = 0.008 by an unpaired, two-tailed t-test, 
n = 4). (C) Immunofluorescent labeling discloses that 3 d of TRULI treatment elevates the 
cell-cycle marker Ki67 (arrowheads) in cardiomyocytes. Scale bars, 50 µm. 
(D) Quantification again reveals significant effects for Ki67 (p = 0.001 by an unpaired, 
two-tailed t-test, n = 4). (E) A marker of mitotic initiation, pH3, is similarly elevated by 
treatment (p = 0.026 by an unpaired, two-tailed t-test, n = 4). (F) The cardiomyocyte 
solidity, an index of cellular shape, decreases significantly after treatment, an effect 
consistent with de-differentiation (p < 0.0001 by an unpaired, two-tailed t-test, n = 232 
control cells and 197 TRULI-treated cells). (G) TRULI treatment reduces the areas of 
cardiomyocytes, another sign of mitosis (p < 0.0001 by an unpaired, two-tailed t-test, 














































































































































Figure 5.2| TRULI activates Yap in human retinal organoids, driving proliferation. 
(A) A protein immunoblot indicates that 24 hr of treatment with TRULI decreases the 
phosphorylation of Yap in Sox9-marked Müller cells of human retinal organoids. (B) A bar 
graph documents the effect observed in panel A (p = 0.024 by an unpaired, two-tailed 
t-test, n = 3). (C) After 5 d of TRULI treatment, EdU labeling shows a substantial increase 
in cellular proliferation. (D) A bar graph quantifies the result of panel C in three 
experiments (p < 0.0001 by an unpaired, two-tailed t-test, n = 15 control organoids and 












































































Further Characterization of TRULI and its Derivatives 
 
In collaboration with the Tri-Institutional Therapeutics Discovery Institute (TDI) we were 
able to characterize various aspects of TRULI, and the techniques we employed 
originally became the pipeline with which to screen derivatives generated through 
medicinal chemistry. In addition to the in vitro kinase assay we used in our laboratory, 
we developed an in-cell assay for determining the half-maximal effective concentration 
of TRULI on Lats-mediated Yap phosphorylation in live cells. When combined with data 
generated by TDI, both in house and through contract research organizations, these 
techniques demonstrated that TRULI is a direct, potent, and relatively selective inhibitor 
of Lats1/2 kinases. After several generations of optimization, lead compounds 
demonstrated 1000-fold increases in in vitro potency and more than 10-fold increase in 
in-cell potency and mouse utricle explant sensitivity. The most potent derivatives also 
halved the time required for the effect in utricle explants, a promising development for in 
vivo applications. The final suite of derivates varies across systemic stability, potency, 
selectivity, and more, yielding a diverse arsenal of compounds that may contain 
components matching the needs of future biological investigations.  Because these 
compounds are protected under a provisional patent, and much of the intellectual work 
of designing derivatives was done by TDI, the process of compound optimization is 
 55 
described in abstract terms, with a focus on elements performed or analyzed in our 
laboratory. 
 
Section 6.1: In-Cell Potency 
To determine the in-cell potency of TRULI, we evaluated the content of total Yap 
and phospho-Yap in HEK293A cells serum-starved in the presence of various 
concentrations and determined the half-maximal effective concentration of the compound 
to be 510 nM (Fig. 6.1). 
 
Section 6.2: Data from Tri-Institutional Therapeutics Discovery 
Institute 
To assess the selectivity of TRULI, collaborators at TDI first compared the 
sequences of the putative ATP-binding residues of Lats1 and Lats2 with those of other 
members of the AGC kinase family25,44. To determine which of these potential off-target 
kinases are bound, we tested TRULI in a broad kinome-binding panel45. Of the 314 
kinases tested, 34 bound TRULI more strongly than did Lats1 (Table 6.1A). These values 
likely represent an upper bound on the number of enzymes susceptible to cross-reactivity: 
although only kinases bound by a small molecule might be relevant, not all such enzymes 
are functionally inhibited. The selectivity score, or percentage of kinases for which the 
inhibitor has an half-maximal displacement concentration below 1 µM, was 18.1. This 
value compares with 86.0 for the broad-spectrum kinase inhibitor staurosporine and with 







Figure 6.1| In-cell determination of TRULI potency. A kinase assay conducted with 
serum-starved HEK293A cells indicates a half-maximal effective concentration of 510 nM 

































Table 6.1| Specificity of TRULI in binding and function. Colors identify different sub-
families of the AGC kinase family. (A) Of 314 kinases in a binding panel, the indicated 
enzymes bound 1 µM TRULI more strongly than did Lats1 or Lats2. The assay did not 
test for functional inhibition. (B) Half-maximal inhibitory concentrations (IC50s) of TRULI 



















































whether some of the kinases identified in both approaches were in fact functionally 
inhibited, we measured half-maximal inhibitory concentration values against four kinases 
that were high on both lists and represented by multiple family members (Table 6.1B)46. 
Confirming our assumption, the range of inhibitory potency spanned from 14 nM, a 
relatively strong inhibition, to 1000 nM, effectively no inhibition. Although it will be 
necessary to explore other potential off-target kinases, particularly in a tissue-specific 
context, these data demonstrate that TRULI is a potent, direct, and relatively selective 
inhibitor of Lats1 and Lats2. 
To explore the broader characteristics of TRULI, TDI also performed standard 
metabolic and toxicology analysis, establishing starting points for the next stage of 
compound optimization.  
 
Section 6.3: Medicinal Chemistry  
Drawing on an extensive background of expertise, medicinal chemists from TDI 
used the limited information at hand to optimize compounds. After dozens of compounds 
had been designed and synthesized, our group performed the in vitro kinase assay, 
always with controls of TRULI, to look for improved potencies. Superior compounds were 
noted, and TDI gleaned the lessons from the data, informing new generations of 
derivatives. Particularly good compounds from each generation were repeated in the in 
vitro kinase assay and then assessed in the in-cell assay. 
TRULI was optimized across its three moieties (Fig. 6.2):  hinge-binding, core, and  






Figure 6.2| Medicinal chemistry approaches. TRULI comprises three regions: a 
thiazolimine backbone (green), a hydrophobic benzyl group (blue), and a 7-azaindole 




yielded complete loss of inhibition. Although many modifications within the core and 
hydrophobic regions were also found to decrease potency, numerous alterations were 
found that dramatically increased the compounds’ potencies.  
In addition to our assessment of derivative potency, TDI performed 
pharmacokinetic, toxicity, and specificity studies on the best derivatives of each 
generation to assess for improvements along these other key characteristics.   
 
Section 6.4: Lead Compounds  
After 60 compounds had been made over a period of six months, the best were 
1000-fold more potent than TRULI in the in vitro kinase assay and up to 50-fold more 
potent in mouse utricle explants (Fig. 6.3). Of particular interest for in vivo pursuits, the 
best compounds were not only more potent, but also halved time required for an effect 
in adult mouse utricle explants, at a 10-fold lower dosage than TRULI is used (Fig 6.4).  
The contract research organization-based analyses also rounded out the 
characterization of this suite, wherein some compounds demonstrate better specificity, 
some better solubility, some high and some low systemic stabilities (Table. 6.2). 
Altogether, this suite offers a robust arsenal of tools for a variety of needs of future 







Figure 6.3| Increased potency of derivatives. Concentrations as low as 100 nM of some 
derivatives sufficed to drive supporting cell proliferation in adult murine utricle explants. 

















Figure 6.4| Decreased response latency in derivatives. In vitro treatment of adult 
utricle explants with 1 µM of one derivative for only three days elicited robust proliferation; 
by comparison, TRULI requires five days at 10 µM for a comparable response. Two 
representative images are shown. Nuclei are labeled with DAPI (blue), and nuclei of 













Table 6.2| Derivatives of TRULI. Two derivatives are shown compared to TRULI and its 
qualities, as characterized by both in-house assays and information generated by TDI 
through contract research organizations. Green indicates optimal ranges, yellow 
intermediate values, and red poor quality. Half-maximal inhibitory concentrations (IC50), 
as measured in the in vitro kinase assay, are noted in nanomolar. Over 60 derivatives 






























Most experiments demonstrating the regenerative effects of Yap activation in 
mammalian tissues have used transgenesis, viral transfection, or indirect approaches 
such as activation of G protein-coupled receptors. Although these studies have provided 
important proof-of-principle results, manipulation of Yap signaling with small molecules 
offers a more feasible translational approach and simplifies further investigations. In the 
work described thus far, our group identified and characterized TRULI, a small-molecule 
inhibitor of the LATS1/2 enzymes. The results supported our original hypothesis that 
Yap activation in adult murine utricle would drive supporting cell proliferation. Moreover, 
TRULI reproduces findings from cardiomyocyte and retinal tissues, suggesting the 
compound and its derivatives are broadly applicable to any investigator interested in 
exploring Lats inhibition or Yap activation. Although in vivo studies with TRULI suggest 
that its pharmacokinetic properties are insufficient for this application, the dozens of 
superior derivatives generated significantly increase the likelihood of success in this 
endeavor. TRULI and its derivates offer powerful tools for molecular investigations of 
development, stem cell biology, regeneration, and more; it is even plausible that drugs 
related to this novel thiazolimine class will prove useful in some therapeutic contexts. 
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Section 7.1: Next Steps in the Inner Ear  
TRULI offers a novel avenue into investigating the possibility of mitotic regeneration in 
the mammalian inner ear. The next steps to achieve this goal include further 
characterizing and optimizing the transdifferentiation of supporting cells into mature hair 
cells, exploring the potential for Yap reactivation in the cochlea, and finally 
demonstrating any and all of these steps in vivo.  
The initial data on hair cell generation are promising. RNA-sequencing analysis 
done by Dr. Ksenia Gnedeva showed that TRULI treatment reprograms supporting cells 
in the utricle to a more plastic state25. After undergoing division, supporting cells re-enter 
G0 upon drug withdrawal, and many cells shift their nuclei into the hair-cell layer; the 
pattern is strikingly similar to the regenerative response in non-mammalian vertebrates6. 
Although without a second perturbation in vitro, we did not observe markers for mature 
hair cells by immunohistochemistry, daughter cells upregulate hair cell genes to a modest 
extent. Notch inhibition with gamma-secretases failed to improve the 
immunohistochemical readout. However, upon Atoh1 transduction, these cells 
upregulated Pou4F3, an early hair cell marker. Further characterization of the possible 
new hair cells is needed, including assessing electrophysiological activity, channel 
patency, hair bundle formation, and other markers of maturity. The experiments 
conducted heretofore involved explant culture, a fairly toxic environment for hair cells, 
and therefore the system might simply have been incompatible with the generation of fully 
mature hair cells. Taken together, our data suggest that combining Hippo inhibition with 
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a second perturbation driving transdifferentiation might constitute an effective approach 
to restoring hair cells. 
One primary reason for using the utricle as a model organ is that the adult cochlea 
is difficult to culture in explants and in vivo approaches are technically challenging. 
Because a neonatal cochlea explant survives for days in culture, we were able to assess 
the effect of TRULI in this context. After five days of exposure, supporting cells largely 
remained quiescent, but there were strong proliferative effects in the greater epithelial 
ridge, a transient developmental tissue thought to harbor precursor cells for the sensory 
epithelia. Several issues might be at play. One key factor in several regenerative fields is 
that proliferative responses are minimal without damage. In the adult utricle explant, it is 
known that over half of the hair cells die in culture within 24 hours, which might enable 
the proliferation we observe. The hair cells of the neonatal cochlea remain intact, 
however, which might preclude supporting cell proliferation. Moreover, the epigenetic 
status of cochlear cells has been shown to be more restrictive, and the chromatin less 
accessible, than is the case for the utricle47. These factors suggest that either damage, 
more potent derivatives, or longer exposure might tip the scales towards regeneration. If 
these approaches fail to drive supporting cell proliferation, multiple pathways might need 
to be targeted. As described in the Introduction, several cyclin kinase inhibitors are active 
in the cochlea, but not in the utricle, offering other potential targets.  
Many of the aforementioned issues stem from the robust, but problematic, explant 
system. We must ultimately prove the utility of Yap activation in vivo. Although technically 
more challenging, this approach circumvents many of the issues at hand. The tissue is in 
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its endogenous context, replete with its natural nutrients, growth factors, and blood 
supply, in the correct ionic milieu, and more. With techniques that have been developed 
to induce hair cell loss specifically, and without effecting the other cell types, we can 
ablate these cells, followed by treatment with TRULI or its superior derivatives. Given the 
pharmacokinetics of the compounds, the use of slow-release gels injected into the middle 
ear will likely be a key aspect of our future approach. These experiments will enable us 
to answer the remaining questions: can daughter cells in the utricle convert into mature, 
functioning hair cells in the endogenous context, or is a second perturbation required; and 
can Yap activation drive supporting cell in the mature organ of Corti? 
 
Section 7.2: Other organs 
Because TRULI can drive the proliferation of murine cardiomyoctyes and human Müller 
cells, we believe that the compound could be widely applicable to various lines of 
investigation into Hippo-Yap signaling. This pathways has been implicated in the 
development of many tissue types; regeneration in the liver, intestine, lungs, and skin; 
cancer45; numerous neurodegenerative diseases48; regulation of the mitotic spindle49; 
cross-talk with important pathways such as Wnt50, p5351, Notch52, and estrogen 
receptor51; and more. To further demonstrate the breadth of utility, we have initiated 
several collaborations that have in part validated our expectations.  
A potential concern about Lats inhibition is oncogenic transformation. The side 
effects of Lats inhibition might be mitigated by local application in isolated fluid 
compartments such as the endolymph of the inner ear, vitreous humor of the retina, and 
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pericardium of the heart. Moreover, the relationship of Yap to cancer is complex. Yap 
activation is a marker for poor prognosis in some cancers, but the opposite is true in other 
instances49. Mutations of proteins in the Hippo pathway are rarely causative of cancer, 
but are instead secondary to the molecular changes associated with tumorigenesis15. In 
fact, activation of Yap through deletion of Lats kinases in certain syngenic tumors 
decreases their progression and metastasis in immune-competent mice by augmenting 
the immune response44. Given these results, we have established a collaboration with Dr. 
Elaine Fuchs at Rockefeller University. Together, we will explore whether Yap activation 
can mimic the effect of Lats deletion in these contexts. We hypothesize that treatment of 
squamous cell carcinomas with TRULI in mice will slow tumor progression and decrease 
metastasis. 
Among the neurodegenerative disease, the role of Hippo-Yap signaling is the 
best characterized in the pathophysiology of Huntington’s Disease54,55. One study 
demonstrated that Yap activation in the nervous system of a mouse model of the 
disease ameliorates behavioral deficits in vivo54. To test whether TRULI sheds light on 
the mechanism of Huntington’s Disease, or offer insights into potential therapies, we are 
collaborating with a team from Dr. Ali Brivanlou’s group at Rockefeller University. Using 
human induced pluripotent stem cell (iPSCs)-derived neuruloids with mutations in the 
huntingtin protein, we hope to explore the developmental relevance of deregulated Yap 
signaling in Huntington’s Disease. 
Yap activation has also been shown to augment the process of converting 
fibroblasts to iPSCs56,57. To explore whether TRULI offers either an investigatory tool or 
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a tool for improved iPSC generation, we have established a collaboration with Dr. Todd 
Evans at Weill Cornell Medical College. Together we are assessing whether TRULI can 
improve the generation of mouse and human iPSC’s, and furthermore we are exploring 
what aspects of molecular biology within these systems this compound might illuminate.  
Within our own group, we have also applied TRULI to the study of regenerating 
neuromasts in the zebrafish. It is poorly understood how the number of sensory hair 
cells is so tightly controlled, and the molecular signals underlying the regeneration these 
cells are only partially understood. We are using TRULI to explore whether Hippo/Yap 
signaling plays a role in this context; our preliminary results strongly suggest this 
pathway is highly relevant to the process.  
We are also continuing our collaboration with Drs. Aaron Nagiel and Ksenia 
Gnedeva, who are attempting to extend our findings in retinal organoids to the retina in 
vivo. We hope that the use of TRULI’s derivatives offers an approach to retinal 
regeneration as well. 
Together, these endeavors demonstrate that TRULI is a widely applicable and 
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Hippo signaling is an evolutionarily conserved pathway that restricts organ growth during 
development and suppresses regeneration in mature organs1–3. Using a high-throughput 
phenotypic screen, we have identified a potent, non-toxic, and reversible inhibitor of Hippo 
signaling. An ATP-competitive inhibitor of Lats kinases, the compound causes Yap-
dependent proliferation of murine supporting cells in the inner ear, murine 
cardiomyocytes, and human Müller glia in retinal organoids. RNA sequencing indicates 
that the substance fosters both the G1-S and G2-M checkpoint transitions and yields 
supporting cells capable of transdifferentiation. Upon withdrawal of the compound, a 
subset of supporting cells move their nuclei into the hair-cell layer and express genes 
characteristic of hair cells. Viral transfection of Atoh1 induces the expression of hair cell-
specific proteins in progeny. The compound promotes the initial stages of the proliferative 
regeneration of hair cells, a process thought to be permanently suppressed in the adult 
mammalian inner ear. 
Introduction 
Initiated in response to injury, regeneration is a complex process that can restore the 
structure and function of damaged tissue. Some adult mammalian tissues retain a 
gradually declining regenerative capability. Regeneration occurs either by activation and 
amplification of resident stem cells, as in the epithelia of the skin and intestine, or through 
cellular de-differentiation and proliferation, as in the liver.  In other instances, such as 
central nervous and cardiac-muscle tissues, cells exhibit little or no potential for 
regeneration after injury1,4,5. 
One prominent example of a mammalian organ with poor regenerative capacity is 
the inner ear6,7. The auditory and vestibular sensory epithelia of all vertebrates possess 
only two major cell types: supporting cells, which play homeostatic and architectural roles, 
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and mechanosensitive hair cells. In non-mammalian vertebrates such as birds, lost hair 
cells are replaced by residual supporting cells that transdifferentiate into new sensory 
receptors either directly or after undergoing division8. Although modest numbers of hair 
cells regenerate through supporting-cell transdifferentiation in the neonatal mammalian 
cochlea9 and in neonatal and adult vestibular organs10, after the first postnatal week no 
proliferative response occurs following damage11,12. 
In view of its fundamental roles in development, proliferation, stem-cell 
maintenance, and de-differentiation, Hippo signaling is an inviting target for driving 
regeneration1,3. The canonical Hippo pathway is a highly conserved signal-transduction 
cascade that comprises two pairs of core kinases. When proliferation is unwarranted, 
Mst1 and Mst2 phosphorylate Lats1 and Lats2; these proteins in turn phosphorylate the 
transcriptional co-activator Yap and its homolog Taz, which as a result are sequestered 
and degraded in the cytoplasm. When the pathway is inactive, Yap enters the nucleus, 
interacts with transcription factors of the Tead family, and initiates cell division2. Yap 
signaling integrates a variety of information from the cellular environment, including 
biomechanical cues, cell density, cell polarity, metabolic challenges, and signals such as 
Notch and Wnt. The Hippo cascade is the conduit through which much, but not all, of this 
information is integrated into a decision regarding Yap activation13.  
The regenerative potential of the Hippo pathway has become abundantly clear in 
numerous organs, including the heart5,14–16, retina17, liver, and intestine18. We earlier 
demonstrated that Hippo signaling limits the size of the developing murine utricle, a 
vestibular sensory organ, and that the Yap-Tead complex is active during—and 
necessary for—proliferative regeneration in the neonatal utricle19. These observations 
suggested that chemical activation of Yap signaling might engender supporting-cell 
proliferation in adult tissue, a key missing step in the regeneration of the mammalian inner 
ear. We therefore conducted a small-molecule screen for Yap activators. 
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Results 
Identification of activators of Yap signaling 
In some monolayer epithelial cultures, increased cell density leads to Hippo activation 
and thus retention and degradation of Yap protein, a process reminiscent of growth 
restriction during normal development20,21,22. To seek inhibitors of this process, we 
designed a high-throughput phenotypic screen for compounds that promote nuclear Yap 
translocation in confluent human cell cultures (Fig. 1A). After testing three lines, we chose 
MCF 10A mammary epithelial cells, which demonstrated a robust negative correlation 
between cellular confluence and the fraction of cells with nuclear Yap (Figs. 1B,C and 
S1A). 
For the small-molecule screen, we seeded MCF 10A cells to achieve dense cultures 
in 384-well plates. A single compound was deposited in each well at a concentration of 
10 µM. Every plate also included a positive control, sub-confluent cells, and a negative 
control, densely cultured cells, both exposed to dimethyl sulfoxide (DMSO) at a 
concentration equivalent to that in which the compounds were applied. After 24 hr 
incubation, we determined the fraction of the cells with nuclear Yap and compared that 
value to the median negative-control value (Fig. 1D). We also scored the total number of 
surviving cells in each well and eliminated the compounds that decreased the number by 
more than one standard deviation in comparison to the dense control cultures. Nontoxic 
compounds that increased nuclear Yap by more than one standard deviation in 
comparison to the negative control were scored as hits (Fig. S1B,C). Owing to the 
robustness of contact inhibition in the dense cell cultures, only six of the compounds 
screened met these criteria. 
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Yap-dependent proliferation of supporting cells evoked by TRULI 
Using utricles isolated from mice eight to twelve weeks of age , we next tested the effects 
of the the six compounds identified in the screen. Four elicited appreciable Yap nuclear 
translocation, but only two evoked supporting-cell proliferation. Of the two proliferation-
inducing compounds, one required a concentration in excess of 100 µM and appeared 
toxic to hair cells. The final compound, N-(3-benzylthiazol-2(3H)-ylidene)-
1H-pyrrolo[2,3-b]pyridine-3-carboxamide, drove robust Yap nuclear translocation after 
24 hr of treatment at a concentration of 10 µM and caused a striking reduction in the level 
of Yap phosphorylation (Figs. 2A,B,D and S2A). After 5 d of treatment, this substance 
evoked robust re-entry into the cell cycle of adult utricular supporting cells (Fig. 2C,E). 
For the sake of brevity we term this substance "TRULI."  
We also tested the recently published inhibitor of Mst1 and Mst2 kinases18, 
XMU-MP-1. Although XMU-MP-1 reduced the amount of phospho-Yap, it decreased the 
total Yap by a greater amount so that the ratio actually increased (Fig. S2A,B). No 
significant proliferation was observed after 5 d of treatment (Fig. S2C). 
We additionally assessed the effect of TRULI in the murine cochlea. Although a 
proliferative response was observed in Kölliker's organ, where progenitor-like cells 
capable of differentiating into both hair and supporting cells reside23,24, all but the most 
lateral rows of supporting cells in the organ of Corti remained postmitotic after treatment 
with TRULI (Fig. S3).  
To test whether the proliferative effect of TRULI is exerted through Yap, we co-
treated explants with TRULI and 5 µM verteporfin, an inhibitor of the interaction between 
Yap or Taz and Tead transcription factors25. Consistent with the hypothesis, co-treatment 
with verteporfin precluded a proliferative response (Fig. 2C,E). To confirm these results, 
we used SOX2-CreER and Yapfl/fl mice to generate inducible conditional-knockout animals 
deficient for the protein in the sensory organs of the inner ear26,27. Owing to the stability 
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of Yap protein28, Cre-mediated recombination was induced either 7 d or 14 d prior to 
utricular explantation and culture. In the utricles isolated from Yapfl/fl littermate mice 
lacking Cre recombinase, treatment with TRULI elicited robust proliferation of supporting 
cells (Fig. 2F,G). In contrast, in utricles explanted from Yap knockout animals, 
proliferation was significantly reduced. 
Blockage of Lats-dependent Yap phosphorylation by TRULI 
We investigated the mechanism of TRULI’s inhibition in the MCF 10A cell line. After 
treatment of confluent cells with 10 μM of TRULI for 24 hr, protein blotting revealed that 
the Hippo signaling cascade was intact through the phosphorylation of the activation 
loops of Lats1 (S909) and Lats2 (S872) (Fig. 3A). However, the phosphorylation of Yap 
at residue S127 was decreased, suggesting that TRULI is—directly or indirectly—an 
inhibitor of Lats kinases. 
To confirm this inference we turned to HEK293A cells, which activate Lats kinases 
in response to serum starvation and thus inactivate Yap to prevent growth during nutrient 
deprivation29,30. We pre-treated 80 % confluent HEK293A cells with 10 μM TRULI for 1 hr, 
followed by 30 min of serum starvation. In control cultures, starvation elicited robust 
phosphorylation of Lats1 at S909 and the consequent phosphorylation of Yap at S127 
(Fig. 3B). In cultures pre-treated with TRULI, however, serum starvation failed to evoke 
phosphorylation of Yap despite the activation of Lats1. Even under treated, serum-fed 
conditions, phospho-Yap levels were below those of serum-fed control cells. Negative-
feedback regulation in response to elevated Yap activity might explain why the amount of 
Lats1 S909 was enhanced in the treated, serum-fed condition31. These results together 
confirmed that TRULI interferes with the ability of Lats kinases to phosphorylate Yap. 
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Direct inhibition of Lats1 and Lats2 by TRULI 
The structure of TRULI includes a 7-azaindole moiety characteristic of the hinge-binding 
motifs of ATP-competitive kinase inhibitors (Fig. 3C) Because there are no known crystal 
structures of the Lats kinases, we created a homology model from the crystal structure of 
the ATP pocket of similar kinase ROCK1 bound to a small-molecule inhibitor containing 
a 7-azaindole moiety. A putative structure of the complex between Lats1 and TRULI was 
then generated by molecular docking (Fig. 3D). Because the predicted protein-ligand 
contact residues of Lats1 and Lats2 are almost completely conserved, the model 
suggests that TRULI can bind either with similar inhibitory potencies. 
To test our speculations about the mechanism of TRULI inhibition, we optimized 
an in vitro kinase assay using truncated forms of Lats1 (residues 589-1130) and Lats2 
(residues 553-1088) that include primarily the kinase domains (Fig. S4A-C). As a 
substrate we employed the peptide STK1, which is known to be phosphorylated by these 
enzymes32. Because we hypothesized TRULI was ATP-competitive, we first determined 
the Michaelis-Menten constants of Lats1 and Lats2 for ATP to be near 10 µM for both 
enzymes, at which we ran the initial in vitro kinase assays (Fig. S4A). Under these 
conditions, we found that TRULI directly inhibits both Lats1 and Lats2 with a half-maximal 
inhibitory concentration (IC50) of 0.2 nM (Figs. 3E and S4D), whence the name TRULI: 
“The Rockefeller University Lats inhibitor." In support of our hypothesis, increases in ATP 
concentrations yielded positive shifts in the IC50 (Fig. 3E).  
To determine the potency of TRULI in living cells, we evaluated the content of total 
Yap and phospho-Yap in HEK293A cells serum-starved in the presence of various 
concentrations of TRULI. The half-maximal effective concentration of the compound was 
EC50 = 510 nM (Fig. 3F). 
To assess the selectivity of TRULI, we first compared the sequences of the 
putative ATP-binding residues of Lats1 and Lats2 with those of other members of the 
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AGC kinase family (Tables S1 and S2)33. To determine which of these potential off-target 
kinases are bound, we tested TRULI in a broad kinome-binding panel34. Of the 314 
kinases tested, 34 bound TRULI more strongly than Lats1 (Table S3). These values 
represent an upper bound: although only kinases bound by a small molecule might be 
relevant, not all such enzymes are functionally inhibited. The selectivity score, or 
percentage of kinases for which the inhibitor has a half-maximal concentration of binding 
displacement below 1 µM, was 18.1. This value compares with control values of 86.0 for 
the broad-spectrum kinase inhibitor staurosporine and of 18.8 for dasatinib, a clinically 
approved selective inhibitor of tyrosine kinases. To assess whether some of the kinases 
identified in both approaches were in fact functionally inhibited, we measured IC50 values 
against four kinases that were high on both lists and represented by multiple family 
members35. Some were affected significantly more strongly than others (Table S4). 
Although it will be necessary to explore other potential off-target kinases, particularly in a 
tissue-specific context, these data demonstrate that TRULI is a potent, direct, and 
relatively selective inhibitor of Lats1 and Lats2. 
Gene-expression consequences of TRULI treatment 
To characterize the consequences of Lats-kinase inhibition with TRULI, we analyzed the 
changes in gene expression triggered by the compound after 5 d of treatment. To facilitate 
the sorting of supporting cells from treated utricles, we utilized Lfng-EGFP mice, whose 
supporting cells bear a fluorescent tag36. Principal-component analysis of RNA-
sequencing data revealed that almost 60 % of the variance between TRULI-treated and 
control samples could be explained by the first principal component and that the three 
samples collected under each condition clustered closely along that axis (Fig. 4A). Over 
70 % of differentially expressed genes whose expression changed by at least a factor of 
two were upregulated after treatment (Fig. 4B). Gene ontology analysis37 demonstrated 
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that the terms associated with regulation of the cell cycle were the most enriched amongst 
up-regulated genes (Fig. 4C). 
To assess the biological relevance of the changes in gene expression triggered by 
TRULI, we compared the FPKM values for the differentially expressed genes to those 
from late embryonic (E17.5) utricular supporting cells. At that stage such cells remain 
highly plastic and are capable of both proliferation and differentiation into the new sensory 
receptors38,39. The expression levels for most cell cycle-related genes (gene-ontology 
term 0007049) that were differentially expressed in postnatal supporting cells after TRULI 
treatment were highly similar to those in E17.5 supporting cells (Fig. 4D). In particular, 
the genes specific to the G1-S and G2-M stages of the cell cycle were significantly up-
regulated by TRULI to the embryonic levels of expression (Fig. 4E,F). Consistent with the 
pro-survival role of Yap-Tead signaling, TRULI repressed expression of a subset of 
inflammatory and pro-apoptotic genes. 
The direct targets of the Yap-Tead complex have been identified in other contexts, 
such as in mammary cancer cells40. In accord with the compound's acting as an activator 
of nuclear Yap signaling, over 90 % of confirmed direct downstream targets of Yap-Tead 
complex identified within differentially expressed genes were up-regulated in response to 
TRULI treatment (Fig. 4G,H). Consistent with our demonstration of a role for Yap in the 
development of the utricular sensory epithelium41, most of these Yap-target genes were 
also highly expressed in E17.5 supporting cells. 
Inhibition of Lats kinases by TRULI had no apparent toxic effect on utricular 
supporting cells: genes associated with cell death (gene-ontology term 0008219) 
remained unchanged after treatment (Fig. 4I). 
Supporting-cell differentiation after TRULI treatment 
To determine whether the increased supporting-cell proliferation triggered by TRULI can 
be reversed, we performed EdU pulse-chase experiments following TRULI treatment. The 
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mitogenic effects of Lats inhibition persisted for 24-48 hr after drug withdrawal, for many 
supporting cells incorporated EdU during that interval (Fig. S5). However, most 
supporting cells exited the cell cycle thereafter. 
Forcing postmitotic cells to re-enter the cell cycle can result in arrest at the G1-S 
or G2-M checkpoint transition and consequently in programmed cell death42. To evaluate 
the long-term outcome of Lats inhibition on supporting cells, we treated three-week-old 
Lfng-GFP utricles with TRULI for 5 d followed by 5 d of withdrawal. RNA-sequencing 
analysis demonstrated that the levels of expression for the cell cycle-related genes and 
the direct Yap targets that were highly up-regulated upon TRULI treatment were 
indistinguishable between TRULI-treated and control supporting cells (Fig. S6). In 
addition, we did not observe enrichment for pro-apoptotic genes after TRULI treatment. 
Instead, the up-regulated genes were associated with the gene-ontology terms related to 
hair-cell development and function (Fig. 5A,B). These included the genes for hair cell-
specific transcription factors such as Atoh1, Pou4f3, Gfi1, and Lhx3 as well as genes 
encoding important hair-cell proteins: nonmuscle myosins (Myo15, Myo7A, Myo5A), Ca2+ 
sensors and buffers (Otof, Calb, S100), and transduction machinery (Tmc1, Tomt). 
Because the foregoing results suggested the transdifferentiation of newly formed 
supporting cells, we sought newly formed hair cells by EdU incorporation. Treatment with 
TRULI did not affect hair-cell or supporting-cell survival, confirming that the compound is 
not toxic at the effective concentration (Fig. 5C,D). Although almost none of the cells 
expressed Pou4f3 or Myo7A, many of the EdU-positive supporting-cell nuclei migrated 
into the hair-cell layer. This pattern is consistent with the first stages of transdifferentiation. 
To test whether supporting cells were capable of giving rise to hair cells after they 
had proliferated, we treated P21 utricles with TRULI and virally transfected the cultures 
with Atoh1-RFP upon drug withdrawal. Demonstrating a capacity for transdifferentiation 
into putative hair-cell precursors, many EdU- and Pou4f3-positive cells were observed 
after Atoh1 transfection (Fig. S6D).  
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Effects of TRULI on cardiomyocytes and Müller glia 
Because the regenerative effects of activating Yap in organs such as the retina and heart 
have been characterized extensively5,14,15,17, we investigated whether TRULI treatment is 
effective in eliciting cellular proliferation in these contexts.  
The proliferative capacity of cardiomyocytes in culture and the capacity of the heart 
to regenerate decline sharply after birth5. To ascertain whether TRULI activates Yap and 
induces regeneration, we exposed P0 murine cardiomyocytes to TRULI for 3 d. In control 
cultures, protein blotting revealed high levels of phospho-Yap indicative of Hippo activity. 
TRULI treatment reduced the proportion of phosphorylated Yap and induced 
cardiomyocyte proliferation, as demonstrated by a significant increase in the percentage 
of cells positive for the markers Ki67 and phosphorylated histone H3 (Fig. 6A-E). 
Moreover, treated cells developed cytoskeletal rearrangements and protrusions and 
decreased in size, phenotypes consistent with de-differentiation and proliferation, 
respectively (Fig. 6F,G)43. 
Yap activation may permit retinal regeneration in mammals by stimulating the 
proliferation of Müller glial cells, progenitors with a capacity to differentiate into 
photoreceptors and neurons17,44. To test whether TRULI induces the proliferation of 
Müller glia, we used retinal organoids derived from human induced pluripotent stem cells. 
As expected, Müller cells remained largely quiescent in control cultures. In organoids 
treated for 5 d with 10 µM TRULI, however, Müller cells exhibited a robust increase in 
proliferation (Fig. 6H-K). 
Discussion  
Most experiments demonstrating the regenerative effects of Yap activation in mammalian 
tissues have used transgenesis, viral transfection, or indirect approaches such as 
activation of G protein-coupled receptors by sphingosine-1-phosphate or epinephrine. 
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Although these studies have provided proof-of-principle results, manipulation of Yap 
signaling with small molecules represents a more feasible translational approach. In fact, 
the only other published inhibitor of the Hippo pathway, XMU-MP-1, activates Yap 
signaling and facilitates healing of the liver and intestinal epithelium after damage18. It is 
noteworthy, however, that in our hands XMU-MP-1 did not promote supporting-cell 
proliferation in the utricle. This result suggests that other enzymes function redundantly 
to Mst kinases in the sensory epithelia. These likely include the Map4K kinases, which 
activate Lats kinases in other contexts45. In fact, our RNA-sequencing data revealed that 
Map4K2, Map4K3, and Map4K4 are all highly expressed in the adult murine utricle. To 
our knowledge, no enzymes are broadly redundant to Lats1 and Lats2. Inhibition of Lats 
kinases with TRULI might therefore provide an effective means of inactivating Hippo 
signaling in a variety of tissues. 
Re-entry into the cell cycle is only one component of regeneration; the daughter 
cells must also assume their correct cell fates. Our data suggest that, in addition to 
inducing proliferation, TRULI treatment leaves newly formed supporting cells in a plastic 
state. After undergoing division, supporting cells re-enter G0 upon drug withdrawal, and 
many cells shift their nuclei into the hair-cell layer and activate expression of characteristic 
hair-cell genes; the pattern is strikingly similar to the regenerative response in non-
mammalian vertebrates8. Because these cells can initiate transdifferentiation upon Atoh1 
overexpression, combining Hippo inhibition with inhibition of Notch signaling or Atoh1 
gene therapy might constitute an effective approach to restoring hair cells. 
In contrast to the robust response in the adult murine utricle, the vast majority of 
supporting cells in the neonatal cocTiktaalikhlea remained quiescent after 5 d of TRULI 
treatment. A wave of transcriptional up-regulation of Cdkn1B, the gene encoding 
P27Kip1, is known to control both the timing and the pattern of cell-cycle exit in the organ 
of Corti46. This process seems absent from the utricle. Activation of Wnt signaling 
promotes proliferation in the neonatal organ of Corti, but the effect primarily involves 
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Kölliker's organ and the lateral Hensen's cells47,48,49,50. This pattern resembles that 
observed after treatment with TRULI. To facilitate cell-cycle re-entry, the organ of Corti 
might require a more prolonged exposure to proliferative stimuli or treatments that target 
multiple signaling pathways. 
Although pharmacological manipulation of the Hippo pathway might prove useful 
in dealing with many human diseases, much remains unknown about the potential pitfalls 
of Lats inhibition. In the context of the Hippo pathway Lats1 and Lats2 are considered 
redundant, but each paralog also has unique functions such as estrogen-mediated 
signaling and p53 regulation, respectively. Furthermore, Lats kinases and Yap have 
ancient and conserved non-Hippo functions in spindle-assembly checkpoints and 
cytokinesis51. TRULI also offers the ability to investigate these non-Hippo functions of 
Lats kinases, and it would be prudent to understand the implications of Lats inhibition on 
these pathways prior to therapeutic endeavors. 
Another potential concern about Lats inhibition is oncogenic transformation. In this 
regard the effect of systemic inhibition of Mst kinases is encouraging18: even after long-
term administration, no oncogenic transformation was observed in mice treated with 
XMU-MP-1. Moreover, the impact of Lats inhibition might be mitigated by local application 
in isolated fluid compartments such as the endolymph of the inner ear, vitreous humor of 
the retina, and pericardium of the heart. Finally, the relationship of Yap to cancer is 
complex. Yap activation is a marker for poor prognosis in some cancers, but the opposite 
is true in other instances52. Mutations of proteins in the Hippo pathway are rarely 
causative of cancer, but are instead secondary to the molecular changes associated with 
tumorigenesis3. In fact, activation of Yap through deletion of Lats kinases in certain 
syngenic tumors decreases their progression and metastasis in immune-competent mice 
by augmenting the immune response53. 
In summary, TRULI is a potent, non-toxic, and reversible inhibitor of Lats kinases, 
and thus a powerful tool for exploring the role of Hippo signaling in a variety of biological 
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contexts. As expected on the basis of prior work, Yap activation with TRULI induces the 
proliferation of murine neonatal cardiomyocytes in primary culture and of human Müller 
glia in retinal organoids. Moreover, the sensory epithelia of the inner ear now join the list 
of tissues amenable to Yap-mediated regeneration. In view of the ubiquity of these 
effects, it is plausible that drugs related to this novel thiazolimine class will prove useful 
in therapeutic contexts. 
Materials and Methods 
Animal care and strains 
Experiments were conducted in accordance with the policies of the Institutional Animal 
Care and Use Committees of The Rockefeller University, the University of Southen 
Califiornia, and the Weizmann Institute of Science. 
Swiss Webster mice were obtained from Charles River Laboratories. Sox2-CreER, 
aMHC-Cre, and ROSA26-tdTomato mice were obtained from the Jackson laboratory. 
Yapfl/fl (Zhang et al., 2010) were provided by Dr. Martin, Baylor College of Medicine.  
Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by 
intercrossing aMHC-cre mice54, which exhibit highly efficiency recombination in 
cardiomyocytes, with ROSA26-tdTomato mice55 that require Cre-mediated recombination 
for expression. Both lines were maintained on a C57BL/6 background. 
Chemical libraries 
A total of 140,238 different compounds from a library at The Rockefeller University High-
Throughput and Spectroscopy Resource Center were chosen by a quantitative estimate 
of drug-likeness score56. The compounds originated in the following commercially 
available libraries: ChemDiv (San Diego, CA), Enamine (Monmouth Junction, NJ), 
BioFocus (Charles River, Wilmington, MA), ChemBridge (San Diego, CA), Specs 
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(Zoetermeer, The Netherlands), Life Chemicals (Niagara, Canada), and AMRI (Albany, 
NY). Compound stocks were stored in 384-well polypropylene plates at a final 
concentration of 5 mM in DMSO at -30 ˚C.  
High-throughput screen for small-molecule activators of nuclear Yap 
Three human epithelial cell lines, one human embryonic kidney 293 line (HEK293T), and 
two human mammary gland epithelia lines (MDA-MB and MCF 10A), were tested for the 
screen. Of the three lines, only MCF 10A cells display a reproducible correlation between 
the number of cells seeded and the number of cells adhered after 24h in culture and thus 
were selected for the screen. 
MCF 10A cells (ATCC CRL-10317) were cultured in a medium comprising 
DMEM/F12, 5 % horse serum (Invitrogen 16050-122), 20 ng/L epidermal growth factor 
(Millipore GF155), 0.5 mg/L hydrocortisone (Sigma H-0888), 100 ng/L cholera toxin 
(Sigma C-8052), 10 mg/L insulin (Sigma I-1882), and antibiotic-antimycotic solution. Cell 
cultures reached 100 % confluence at an approximate density of 3·105 cells per square 
millimeter.  
For the small-molecule screen, chemical-library plates were thawed at room 
temperature and 0.1 μL of each compound was placed in a well of a 384-well assay plates 
(Greiner Bio-One) containing 10 μL of MCF 10A culture medium (PerkinElmer Janus with 
Nanohead). MCF 10A cells were then plated in 40 μL of MCF 10A culture medium to 
achieve a final concentration of 10 µM for each compound and 0.25 % (vol/vol; 35 mM) 
dimethyl sulfoxide. Negative (100 % confluent) and positive (25 % confluent) control wells 
included an identical concentration of the DMSO vehicle. 
After 24 hr incubation, the cells were fixed, washed thrice in PBS, and 
immunolabeled for Yap. The nuclei were stained with 3 mM 4,6-diamidino-2-phenylindole 
dihydrochloride (DAPI). The plates were imaged automatically with a 10X objective lens 
on the ImageXpress XLS wide-field Micro reader (Molecular Devices, Sunnyvale, CA) 
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with MetaXpress software (Molecular Devices). Using an empty plate to avoid out-of-
focus images, we configured a laser-based autofocus routine for automatic well-bottom 
detection. We imaged DAPI and Yap conjugated to Alexa Fluor 488 with filter cubes for 
respectively DAPI (excitation, 350-400 nm; emission 415-480 nm) and FITC (excitation, 
460-505 nm; emission, 510-565 nm). The acquisition system was configured to image 
one site per well. After the fluorescence of DAPI had been used to set the image-based 
autofocus, the exposure time for each fluorophore was determined with a negative-control 
well in which the fluorescence signal was set to 75 % of the camera’s maximal intensity. 
An image-segmentation application from MetaXpress software was used to 
automatically analyze the images. The number of cells was estimated by selecting an 
average size and intensity level above the local background in the DAPI channel.  
A built-in translocation module that measured the intensity movement from one 
compartment to another was configured to determine the nuclear or cytoplasmic status 
of the Yap. These measurements were acquired first for the positive and negative control 
wells to determine an arbitrary threshold for the intensity ratio that characterized nuclear 
translocation versus cytoplasmic retardation of Yap. The same threshold was then 
applied to each well treated with a small-molecule to identify the substances that 
increased the number of cells with nuclear Yap without affecting cell survival. Positive 
controls were not used to normalize data, but to confirm whether the cells were healthy 
and behaving as expected. 
Images were stored in the MDCStore database and analyzed using MetaXpress 
software (Molecular Devices). Output data were uploaded and analyzed using the CDD 
Vault from Collaborative Drug Discovery (Burlingame, CA). 
The compounds showing over 10 % Yap nuclear translocation and over 5,000 cells 
per field were selected and the corresponding images were checked to verify the 
phenotype. To determine half-maximal inhibitory concentrations, the selected compounds 
were re-tested in concentration-response experiments by serially diluting by half for a total 
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of ten dilutions to achieve assay concentrations ranging from 20 µM to 0.03 µM. IC50s 
values were calculated by CDD software. Six compounds were confirmed in this 
secondary screen.  
Small-molecule Lats inhibitor 
The compound N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-
3-carboxamide (CAS number 1424635-83-5), of relative molecular mass 334.4 Da and 
herein termed TRULI, was obtained from Enamine LLC (Z730688380, Monmouth 
Junction, NJ). 
Dissection and culture of inner-ear sensory epithelia 
Internal ears were dissected from mice euthanized with fluothane and placed into ice-cold 
Hank’s balanced salt solution (HBSS; Gibco14025-092)57. 
Unless indicated otherwise, explanted cultures of the utricle and cochlea were 
maintained in an incubator at 37 ˚C in the presence of 5 % CO2 and 95 % O2. The 
complete growth medium comprised Dulbecco's modified Eagle medium with nutrient 
mixture F-12 (DMEM/F12) supplemented with 33 mM D-glucose (Sigma G8644), 19 mM 
NaHCO3 (Sigma S8761), 15 mM HEPES (Sigma H0887), 1 mM glutamine (Sigma 
G8540), 5 mM nicotinamide (Sigma N0636), 40 µg/L epidermal growth factor (Sigma 
E9644), 20 µg/L fibroblast growth factor (Sigma F5392), insulin-transferrin-selenite 
solution (Sigma 11074547001), and antibiotic-antimycotic solution (Gibco 15240062). 
For proliferation assays, utricles were cultured with 10 µM 5-ethynyl-
2¢-deoxyuridine (EdU) that was detected with click chemistry (Click-iT EdU imaging kit, 
Thermo C10340). 
Culture of epithelial cells 
MCF 10A cells were cultured as described above. HEK293A cells were maintained in 
DMEM (Gibco 11965-092), 10 % fetal bovine serum (Sigma F2442), and antibiotic-
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antimycotic solution. All cells were incubated at 37 ˚C in the presence of 5 % CO2 and 
95 % O2. 
Culture of primary cardiomyocytes 
Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by 
intercrossing aMHC Cre mice54, which exhibit highly efficiency recombination in 
cardiomyocytes, with ROSA26-tdTomato mice55 that require Cre-mediated recombination 
for expression. Both lines were maintained on a C57BL/6 background. 
Neonatal primary cardiac cultures were isolated from P0 pups with a neonatal 
dissociation kit (Miltenyi Biotec,130-098-373) and homogenizer (gentleMACS). Cardiac 
cultures were seeded in gelatin-coated wells coated with 0.1 % gelatin (G1393, Sigma) 
in DMEM/F12 medium supplemented with 1% L-glutamine, 1 % sodium pyruvate, 1 % 
nonessential amino acids, 1 % penicillin-streptomycin solution, 5 % horse serum, and 
10 % fetal bovine serum. After culture in 5 % CO2 for 24 hr at 37 ˚C, the medium was 
replaced for an additional 72 hr with bovine serum-free medium containing 0.1 % (vol/vol) 
DMSO and, for experimental samples, 20 µM TRULI. 
Culture of human pluripotent stem cells and retinal organoids 
The WTC-11 line of induced pluripotent stem cells (Coriell Institute for Medical Research, 
Camden, NJ) was maintained using standard methods. Human retinal organoids were 
produced from these cells58. In three independent proliferation assays, five organoids 
225-280 d of age per experimental condition were sampled in culture after incubation for 
5 d in 10 µM TRULI and 10 µM EdU. The organoids used in the immunoblot analysis were 
160-178 d of age and were incubated for 24 hr in 10 µM TRULI. 
Immunohistochemistry of murine inner-ear sensory epithelia 
Utricles were fixed in 4 % formaldehyde (Thermo 28906) for 1 hr at room temperature 
and then blocked for 2 hr at room temperature with 3 % bovine serum albumin (BSA; 
Jackson AB 2336846), 3 % normal donkey serum (Sigma-Aldrich D9663), and 0.3 % 
Triton X-100 (Sigma 93443), in Tris-buffered saline solution (Thermo 28358). 
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The primary antisera—goat anti-Sox2 (R&D AF2018), rabbit anti-myosin 7A 
(Proteus 25-6790), mouse anti-Yap (SC-101199), rabbit anti-Sall2 (HPA004162), and 
mouse anti-Pou4F3 (SC-81980)—were reconstituted in blocking solution and applied 
overnight at 4 ˚C. 
Samples were washed with phosphate-buffered saline solution supplemented with 
0.1 % Tween 20 (Sigma-Aldrich), after which Alexa Fluor-labeled secondary antisera (Life 
Technologies) were applied in the same solution for 1 hr at room temperature. 
Nuclei were stained with 3 mM DAPI. 
Immunofluorescence assays for cardiomyocytes 
Cells were fixed in 4 % formaldehyde for 10 min with shaking at room temperature, 
permeabilized for 5 min with 0.5 % Triton X-100 in PBS, and blocked for 1 hr at room 
temperature with 5 % BSA in PBS containing 0.1% Triton X-100. The cells were labeled 
overnight at 4 ˚C with the primary antibodies anti-Ki67 (1:200, 275R, Cell Marque) and 
anti-phosphorylated histone 3 (1:200, 9701, Cell Signaling) for. After three washes with 
PBS, samples were labeled for 1 hr at room temperature with fluorescent secondary 
antibodies (Abcam) followed by 10 min of DAPI staining for nuclear visualization. After 
three washes in PBS, cells were imaged with a Nikon Eclipse Ti2 microscope. 
Immunofluorescence imaging of retinal organoids 
Fresh frozen sections were permeabilized and blocked in a humidified chamber for 1 hr 
at room temperature with 3 % horse serum in PBS with 0.3 % Triton X-100. The slides 
were exposed for 2 hr to primary antibodies diluted in the same solution. Anti-Sox-9 
(1:100, Rb Cell Signaling 82630) was used to mark Müller cells. Slides were washed three 
times with PBS. Secondary antisera (Alexa-Fluor 488 and 647) diluted 1:10,000 in the 
serum solution were added for 1 hr at room temperature followed by two washes with 
PBS. Labeling for 30 min at room temperature (Apply Click-iT Invitrogen Alexa Fluor 555 
C10338) was followed by a wash with PBS. After incubation with DAPI (1:10,000 in PBS) 
for 5 min and the application of mounting solution, sections were imaged by confocal 
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microscopy with a Zeiss LSM 700 system with a 20X/0.8 NA objective lens with a pinhole 
size set at the first Airy disc. 
Protein immunoblotting and quantification 
MCF 10A, HEK293 cells, retinal organoids, and utricles were lysed on ice in 
radioimmunoprecipitation assay buffer solution (RIPA; BP-115-5x) with protease 
inhibitors (Halt Protease Inhibitor Cocktail, Thermo 87786). Utricles were additionally 
sonicated thrice at low power for 10 s, with breaks of 20 s with the samples kept on ice 
between sonications  After lysates had been scraped and centrifuged at 10,000 RPM for 
10 min at 4 ˚C, the supernatants were immediately subjected to electrophoresis or stored 
at -80 ˚C.  
A standard immunoblotting protocol was used with the following specifications. A 
4-12 % bis-tris gel (Thermo NP0322) was used to resolve the proteins in 5 mg of each 
sample. The proteins were transferred to a nitrocellulose membrane (BioRad 1704156) 
and blocked for 1 hr at room temperature (Rockland MB-070). After primary antibodies 
had been reconstituted in the same solution, the membrane was incubated overnight at 
4 ˚C. After three 5 min washes at room temperature in tris-buffered saline solution with 
0.05 % Tween 20, a secondary antibody conjugated to horseradish peroxidase (Millipore) 
was applied in the same solution for 1 hr at room temperature before activity was detected 
(SuperSignal West Pico PLUS, Thermo 34580). Images were acquired with an 
iBrightFL1000 system.  
We used at a dilution of 1:1000 primary antibodies directed against Yap 
(sc-101199), phospho-Yap S127 (CST 4911), Lats1 and Lats2 (Abcam, ab70565), 
phospho-Lats1 S909 (CST 9157), Mst1 (CST 3682), Mob1 (CST 13730), phospho-Mob1 
T35 (CST 8699), tubulin (Sigma T6793), and GAPDH(Abcam ab8245). 
Cultured cardiomyocytes were lysed using RIPA supplemented with protease and 
phosphatase inhibitors (1:100, Sigma). Lysates were prepared and 30 µg protein of each 
sample was fractionated by gel electrophoresis in tris-glycine acrylamide gels, and 
subsequently transferred to a PVDF membrane. Following 1 hr blocking at room 
temperature, membranes were incubated with the following antibodies against 
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phospho-Yap at s112 (1:1000, 13008, cell signaling), Yap (1:2000, NB110-58358, Novus) 
and Rabbit anti GAPDH (1:8000, PLA0125, Sigma) for 1 hr at room temperature. 
Following two washes in tris-buffered saline solution containing 0.1 % Tween 20, 
membranes were incubated with horseradish peroxidase anti-rabbit or secondary 
antibodies (Jackson). The signal was detected by super-signal west pico plus 
chemiluminescence kit (34580, Thermo-Fisher). 
Immunoblots were quantified through measurement of band intensity with Fiji59. 
The final value of each band’s intensity was normalized by the sum of all the bands’ 
intensities. Significances from Student’s t-tests are denoted as follows: *, p < 0.05; **, 
p < 0.01; ***, p < 0.001; ****, p < 0.0001. Unless otherwise indicated, error bars denote 
standard errors of means (SEMs). 
Imaging of Yap nuclearization and quantification of proliferation  
Confocal imaging was conducted with a confocal microscope enhanced with structured 
illumination (VT-iSIM, VisiTech International Ltd.). 
For quantification of Yap nuclearization, for each condition two fields of supporting 
cells were imaged at 60X from two utricles. Using CellProlifer60, we masked Sall2-positive 
nuclei and measured the intensity of their labeling. The same mask was then applied to 
the Yap channel and the intensity of labeling was measured. The ratio of the Yap to the 
Sall2 intensity was calculated for each condition in 680 cells after TRULI treatment and 
570 cells for DMSO controls. 
For quantifying the proliferation of supporting cells, we imaged utricles at 60X, then 
assembled the images into a composite tiling (Grid Collection Stitching, Fiji). The maximal 
values in z-stacks were projected to display the entire supporting-cell layer of the sensory 
epithelium, excluding connective tissue and the surrounding epithelium. Using 
CellProlifer60, we counted the number of EdU-positive nuclei. Alternatively, EdU- and 
Sox2- doubly positive nuclei were counted using Multi-point Tool in ImageJ. 
Images acquired from neonatal cardiac cultures were analyzed using ImageJ 
software by thresholding for cardiomyocytes according to endogenous tdTomato 
fluorescence. Thresholded figures were carefully and manually separated by fine lines to 
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de-cluster cells in case they touch, basing on original images, following by measurements 
of area and solidity.  
Images acquired from retina organoids were analyzed with CellProfiler60. Masks 
were created for all the Sox9-positive nuclei, and the percentage of EdU- and 
Sox9-positive nuclei were counted.  
In vitro kinase assay 
The in vitro kinase assay (HTRF KinEASE-STK S1, CisBio 62ST1PEB) was optimized to 
the linear reaction range of the enzymes Lats1 (Carna 01-123) and Lats2 (Carna 01-124). 
Reactions were conducted with 10 µM STK1 substrate and 10 µM ATP, unless otherwise 
indicated. For the ATP-shift assay, ATP was also used at concentrations of 50 µM and 
250 µM. Lats1 was employed at a concentration of 200 pg/µL and Lats2 at 50 pg/µL, 
unless otherwise indicated. For the assay in which Michaelis-Menten constants for ATP 
were determined, each enzyme was at a concentration of 62.5 pg/uL, and Lats1 ran for 
30 min, and the Lats2 ran for 20 min, all at room temperature. The DMSO concentration 
was maintained at 0.5 % (vol/vol) throughout all experiments, and a Janus 384 MDT 
(PerkinElmer) equipped with a 50 nL Pintool (V&P Scientific, Inc.) was used to add the 
compounds dissolved in DMSO to the reaction. The enzyme, substrate, ATP, and TRULI 
were combined in a low-volume 384-well plate and shaken for 50 min at room 
temperature, unless otherwise indicated. The reaction was stopped by adding the 
detection reagents, which were prepared at an 8:1 biotin:streptavidin ratio, and shaken 
for 60 min at room temperature. All reactions were conducted in triplicate and a Synergy 
NEO (Biotek) was used to detect the signal. 
Cellular kinase assay 
HEK293A cells were plated overnight in 96-well culture plates at a density of 50,000 cells 
per well in the medium described above. To start the assay, new serum-free medium with 
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various concentrations of the compound was added to the cells, which were then 
incubated for 30 min at 37 ˚C. The DMSO concentration was kept at 0.1 % (vol/vol), and 
all experiments were performed in triplicate. 
Total Yap and phospho-Yap were detected according to the two-plate protocol for 
adherent cells (Total Yap Cellular Kit, Cisbio 64YATPEG; phospho-Yap [Ser127] Cellular 
Kit, Cisbio 64YapPEG). The signal was detected by Synergy NEO (Biotek). 
Modeling of enzyme structure 
Lats1 and Lats2 are in the AGC kinase family, which also contains kinase sub-families 
such as Ndr and Rock33. In Homo sapiens, Lats1 has an overall sequence identity of 
51.7% with Lats2, of 42.2% with Ndr2, and of 39.9% with Rock1. Owing to the presence 
of the classic kinase hinge-binding azaindole motif in TRULI, we focused on the kinase 
domain and analyzed the ATP-binding site in order to generate a homology model. To 
define this site we used the 36 kinase-domain residues defined by Huang et al.61. We 
show an alignment of these ATP-binding site residues for 62 human AGC kinases 
(Table S1) and the identities of these residues between Lats and the other AGC kinases 
(Table S2). It is worth noting that the sequence identity between Lats1 and Lats2 in the 
ATP-binding site is 97.2%, with only a single conservative difference (lysine to arginine). 
To generate a homology model of the kinase domain we selected a complex of 
Rock1 bound to an azaindole thiazole inhibitor (PDB ID: 5KKS)62 . This complex was 
selected because the sequence identity between Lats1 and Rock1 in the ATP binding site 
is 72.2% and the bound inhibitor shares an azaindole group with TRULI. Athough the 
resolution of the structure is a modest 0.33 nm (3.3 Å), the electron density within the 
ATP-binding site is good and allows the conformation of the ligand and the amino acid 
side-chains to be determined unambiguously. The protein structure was downloaded from 
the Protein Databank, selenomethionines were changed to methionines, and missing 
sidechains were added with Schrodinger’s Preparation Wizard. This program was also 
used to fix the orientations of the asparagine, glutamine, and histidine residues as well 
as the protonation states of all ionizable residues. Heteroatomic species such as water 
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molecules, buffer solvents. and ions were removed and the complex was energy 
minimized with a restraint of the all-atom root-mean-square distance to 0.03 nm (0.3 Å). 
The homology model was generated from residues 705-1043 of Lats1 with a knowledge-
based model in Schrodinger’s Advanced Homology tool. Chain B of ROCK1 was used as 
the template and the azaindole thiazole inhibitor was retained. 
The resulting homology model was then used for molecular docking with 
Schrodinger’s Glide SP63. The Glide grid was generated around the azaindole thiazole 
inhibitor in the ATP-binding site with T845 as a rotatable group. TRULI was prepared 
using Schrodinger’s Ligprep and docked using Schrodinger’s Glide SP using default input 
parameters. The Glide SP docking score was -39 kJ/mol (-9.4 kcal/mol), corresponding 
to a binding affinity of approximately 130 nM. 
The ligand’s azaindole group is predicted to bind to the hinge region as expected, 
whereas the ligand’s thiazolimine group contacts D846 in the DFG loop and the ligand’s 
benzyl group contacts the C-terminal F1039, which forms the active-site tether in many 
AGC kinases64. 
Although the numbers assigned to the amino-acid residues of various proteins 
elsewhere in the text refer to the murine products, those in the present paragraph 
reference the human proteins. 
RNA sequencing and data analysis 
Supporting cells were isolated by fluorescence-activated cell sorting from the utricles of 
Lfng-EGFP mice as described previously65. The total RNA was extracted using Quick-
RNA MicroPrep kit (Zymo Research) and stored up to 2 weeks at -80 ˚C.  RNA samples 
were then processed for library preparation with QIAseq FX Single Cell RNA Library Kit 
(Qiagen) and the quality of the library was confirmed using a Bioanalyzer (Quick Biology 
Inc.). A minimum of two biological replicates were collected for each condition, and at 
least 20 million 150 base-paired-end reads were sequenced for each replicate. Reads 
were mapped to GRCm38/mm10 genome assembly using STAR66. Differentially 
expressed genes were identified by DESeq267. Only the protein coding sequences were 
considered for FPKM calculation. For data visualization, the ggplot2 package was used 
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(H. Wickham, Springer New York, 2009). Principal components analysis was performed 
with pcaExplorer68 on the 1000 genes whose differential expression was most significant. 
Adenoviral gene transfer 
The AdEasy Adenoviral Vector System (Agilent) was used to create adenoviral vectors 
containing the full-length coding sequence of murine Atoh1 under the control of a 
cytomegalovirus promoter. To permit the identification of infected cells, we also included 
sequences for an internal ribosome-entry site and for RFP. Viral particles were amplified 
and purified by CsCl-gradient centrifugation followed by dialysis (Viral Vector Core 
Facility, Sanford Burnham Prebys Medical Discovery Institute). Utricles were infected in 
200 μL of culture medium with 10 μL of virus at a titer of 1010 pfu/mL. Ad-RFP virus 
(Vector Biolabs) at the same titer were used as a control. 
Supplemental Information 
Supplemental information can be found in the attached file. 
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Figure 1. High-throughput screen for activators of Yap translocation to nuclei 
(A) A schematic diagram demonstrates the strategy for identification of compounds that 
promote the nuclear transit of Yap, thus reversing the exclusion characteristic of contact 
inhibition. (B) The number of MCF 10A cells rises almost linearly with their confluency. 
(C) Nuclear localization of Yap falls systematically with increasing confluency in MCF 10A 
cultures. (D) Immunolabeling of Yap (red) demonstrates nuclear localization of the protein 
in a positive-control (subconfluent) culture and in a negative-control (confluent) culture. 
Treatment of a confluent culture with a representative hit compound promotes extensive 
movement of Yap into nuclei.  

















Figure 2. Activation of Yap and proliferation of supporting cells 
(A) A timeline depicts the pattern of the experiments shown in the indicated subsequent 
panels. Treatment with TRULI is initiated at the outset. (B) TRULI exposure drives Yap 
into the nuclei of utricular supporting cells. (C) In vitro exposure to TRULI for 5 d elicits 
proliferation of supporting cells, as measured by the incorporation of EdU. Verteporfin, an 
inhibitor of the Yap-Tead interaction, drastically reduces this effect. (D) The nuclear 
localization of Yap is quantified as a ratio to the constitutively expressed protein Sall2 
(p < 0.0001 by an unpaired, two-tailed t-test, n = 570 control nuclei and 680 treated 
nuclei). (E) The number of EdU-positive cells per utricle increases with TRULI (p = 0.021 
by an unpaired, one-tailed t-test, control n = 2, TRULI n = 3), but the effect is blocked by 
verteporfin (p = 0.028 by an unpaired, one-tailed t-test, n = 2). (F) Conditional deletion of 
Yap by tamoxifen administration to SOX2-CreER Yapfl/fl  (Yap CKO) animals at P1, 7 d or 
14 d prior to explantation, decreases the number of Sox2 (red) and EdU (white) doubly 
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positive supporting cells compared to Cre-negative Yapfl/fl (WT) littermates. 
(G)  Quantification of the number of EdU-positive cells in panel F demonstrates that 
decrease in supporting-cell proliferation is statistically significant (Student’s t-tests; n = 3 
for wild-type control and Yap CKO at 7 d; n = 4 for TRULI treatment; n = 6 for Yap CKO 
at 10 d and TRULI). 












Figure 3. ATP-competitive inhibition of Lats kinases. 
(A) Protein immunoblotting discloses that treatment of MCF 10A cells with TRULI leaves 
Hippo signaling intact through the activation of Lats kinases, but that Yap phosphorylation 
is greatly diminished. (B) Serum starvation of HEK293A cells in the presence of TRULI 
also demonstrates Lats activation but suppression of Yap phosphorylation. (C) TRULI 
comprises a thiazolimine backbone with two substituents: a benzyl group and a 
7-azaindole hinge-binding motif. (D) In a simulated structure of TRULI in the predicted 
ATP-binding site of Lats1, the protein is displayed as a ribbon with heavy atoms in atom-
colored wire representation with grey carbons. TRULI is displayed in an atom-colored, 
ball-and-stick representation. Aspartate 846 is positioned to bind the thiazolimine group 
and phenylalanine 1039 to interact with the benzyl moiety. (E) An in vitro assay of Lats1 
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kinase activity shows that the IC50 for TRULI increases with the ATP concentration, from 
0.2 nM at 10 µM, to 4.3 nM at 50 µM, and to 80 nM at 250 µM, demonstrating that the 
compound is an ATP-competitive inhibitor. (F) A kinase assay conducted with serum-
starved HEK293A cells indicates an EC50 of 510 nM for TRULI. Starvation does not 
significantly deplete the total amount of Yap. In panels E and F, error bars represent SEs. 




Figure 4. Gene-expression changes evoked treatment in supporting cells by TRULI. 
(A) For three experiments, principal-component analysis was performed on RNA-
sequencing data obtained from supporting cells after 5 d of treatment with TRULI or from 
control samples. (B) A volcano plot visualizes the differentially expressed genes 
(| log2(fold change)  | > 1; padj<0.05). Genes upregulated after TRULI treatment compared 
to control are labeled in red and those downregulated in blue. (C) Gene-ontology (GO) 
analysis performed with DAVID software demonstrates that the terms associated with the 
cell cycle are the most enriched in the genes upregulated by TRULI, whereas the terms 
associated with stress are more enriched in the control gene set. A full list of differentially 
expressed genes identified using DEseq2 is available on request. (D) For three 
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experiments, a heatmap demonstrates the relative expression levels of 140 cell-cycle 
genes differentially expressed between control and TRULI-treated supporting cells (false 
discovery rate < 0.01) in comparison to E17.5. Highly expressed genes are shown in red 
and genes with relatively low levels of expression are depicted in blue. (E) Cell-cycle 
genes of the G1-S transition of the cell cycle are significantly upregulated by TRULI to the 
levels found in E17.5 supporting cells (p < 0.001 by a Wilcoxon signed-rank test). 
(F) Markers of the G2-M transition are likewise upregulated (p < 0.001 by a Wilcoxon 
signed-rank test). (G) For three experiments, the heatmap demonstrates the relative 
expression levels of 79 Yap-target genes differentially expressed between control and 
TRULI-treated supporting cells (false discovery rate < 0.01) in comparison to E17.5 
embryonic levels. (H) The expression of Yap-target genes is upregulated in response to 
TRULI to the levels found in E17.5 supporting cells (p < 0.05 by a Wilcoxon signed-rank 
test). (I) In contrast, the relative level of expression for genes associated with cell death 
remains unchanged between controls, TRULI-treated, and E17.5 supporting cells 
(p > 0.05 by a Wilcoxon signed-rank test). 










Figure 5. Supporting-cell plasticity after TRULI treatment. 
(A) A volcano plot visualizes the genes differentially expressed after 5 d of TRULI 
treatment followed by 5 d drug withdrawal (| log2(fold change)  | > 1; padj < 0.05). The 
subset of hair-cell genes most upregulated after TRULI treatment compared to control 
are labeled. (B) Gene-ontology analysis performed with DAVID software demonstrates 
that the terms associated with hair-cell differentiation and function are the most enriched 
in the genes upregulated by TRULI. A full list of differentially expressed genes identified 
using DEseq2 is available on request. (C) In the representative examples of whole mount 
utricular explants after 5 d of TRULI treatment followed by 5 d drug withdrawal, 
immunolabeling for Pou4f3 (green) and Myo7a (red) depicts hair cells. New sensory 
receptors formed from proliferated supporting cells are identified by EdU-incorporation 
(white) and are found only after TRULI treatment. Nuclei are labeled with DAPI. (D) The 
total number of hair cells per utricle does not change after TRULI treatment (p > 0.05 by 
a Student’s t-test; n = 4 for controls and n = 5 for TRULI treated animals). 
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See also Figure S6. 
 
 
Figure 6. Proliferation of cardiomyocytes and Müller cells. 
(A) A protein immunoblot indicates that TRULI decreases the phosphorylation of Yap in 
neonatal cardiomyocytes in vitro. (B) Quantification of the data in panel A shows the 
significance of the effect (p = 0.008 by an unpaired, two-tailed t-test, n = 4). 
(C) Immunofluorescent labeling discloses that 3 d of TRULI treatment elevates the cell-
cycle marker Ki67 (arrowheads) in cardiomyocytes. Scale bars, 50 µm. (D) Quantification 
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again reveals significant effects for Ki67 (p = 0.001 by an unpaired, two-tailed t-test, 
n = 4). (E) A marker of mitotic initiation, pH3, is similarly elevated by treatment (p = 0.026 
by an unpaired, two-tailed t-test, n = 4). (F) The cardiomyocyte solidity, an index of 
cellular shape, decreases significantly after treatment, an effect consistent with 
de-differentiation (p < 0.0001 by an unpaired, two-tailed t-test, n = 232 control cells and 
197 TRULI-treated cells). (G) TRULI treatment reduces the areas of cardiomyocytes, 
another sign of mitosis (p < 0.0001 by an unpaired, two-tailed t-test, n = 231 control cells 
and 197 TRULI-treated cells). (H) A protein immunoblot indicates that 24 hr of treatment 
with TRULI decreases the phosphorylation of Yap in Sox9-marked Müller cells of human 
retinal organoids. (I) A bar graph documents the effect observed in panel H (p = 0.024 by 
an unpaired, two-tailed t-test, n = 3). (J) After 5 d of TRULI treatment, EdU labeling shows 
a substantial increase in cellular proliferation. (K) A bar graph quantifies the result of 
panel J in three experiments (p < 0.0001 by an unpaired, two-tailed t-test, n = 15 control 
organoids and 16 TRULI-treated organoids). 
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Figure S1.  Screening for activators of Yap translocation into nuclei. Related to Figure 1.  
(A) The adherent properties of three human epithelial-cell lines—one embryonic kidney line (HEK 
293T) and two mammary-gland lines (MDA-MB and MCF 10A)—were tested. Only MCF 10A cells 
display a reproducible correlation between the number of cells seeded and the number of cells 
adhered after 24 hr. (B) In a representative example of cell survival in ten 384-well plates 
screened in the assay for nuclear translocation of Yap, the plate indexes are indicated on the 
x-axis and the total number of cells detected in each well of each plate is indicated on the y-axis. 
Purple lines demonstrate the average mean (M) and one standard deviation (SD) below the mean 
of the number of cells detected in each negative control well (blue dots) of each of the ten plates 
screened. Red dots represent sub-confluent positive control wells; black dots represent each well 
treated with a compound. The substances that decreased the number of cells over one SD were 
eliminated owing to toxicity. (C) In the same ten 384-well plates analyzed in panel B, the 
percentage of cells with nuclear Yap was determined using MetaXpress software. Only one in a 
thousand compounds increased this value more than one standard deviation (SD; purple line) 






































































































Figure S2.  Lack of Yap activation by the Mst inhibitor XMU-MP-1. Related to Figure 2.  
(A) Six utricles per condition were treated for 24 hr with 10 µM TRULI or XMU-MP-1 to assess 
effects on the amount of phospho-Yap by comparison to control conditions. (B) Quantification of 
band-intensity ratios for phospho-Yap and total Yap in the immunoblot of panel A shows that 
XMU-MP-1 does not reduce the fraction of phosphorylated Yap. (C) When adult mouse utricles 
were explanted and cultured with EdU (white) and either TRULI or varying concentrations of 






































Figure S3.  Proliferative response in the cochlea after treatment with TRULI. Related to 
Figure 2. (A) No hair-cell loss is observed after 5 d of treatment of the P1 organ with 10 µM 
TRULI. Only the most lateral rows of Hensen’s cells re-enter the cell cycle after the treatment. 
(B) TRULI elicits robust proliferation of Sox2-positive cells in Kölliker’s organ, as measured by the 








































Figure S4.  Optimization and further results of in vitro kinase assay. Related to Figure 3.  
(A) In order to perform assays at an appropriate ATP concentration, we established the Michaelis-
Menten constants for Lats1 (Km = 9.4 µM) and Lats2 (Km = 7.6 µM). (B)  A kinetic assay for Lats1 
was used to determine the optimal signal-to-noise ratio within the linear range of product 
formation. Enzyme concentrations are indicated in micrograms per liter. (C) The corresponding 
assay was performed for Lats2. (D) The half-maximal inhibitory concentration of TRULI against 
Lats2 was IC50 = 0.2 nM. 
  


























































































Figure S5.  Cell-cycle exit after TRULI withdrawal.  Related to Figure 4.  (A) As shown in the 
timelines to the left, utricles were explanted and cultured for 5 d in the presence of TRULI; EdU 
was then added at various times. In first top row, when EdU was present throughout the 5 d period 
of culture, extensive proliferation occurred in the striolar region. The second row shows that 
proliferation was still heavier when EdU was presented during the day following TRULI exposure. 
The third row indicates that proliferation declined during the second day after TRULI withdrawal. 
The fourth row demonstrates that proliferation fell to nearly the background level when EdU was 
provided three days after the withdrawal of TRULI. (B) A bar graph quantifies the number of EdU-
positive nuclei per sensory epithelium in the foregoing experiments. Each datum is an average 
from two utricles. 
  






































Figure S6.  Cell-cycle exit and hair cell differentiation after TRULI withdrawal.  Related to 
Figure 5.  (A) RNA-sequencing analysis demonstrates that the genes active in G2-M are 
downregulated to the control levels in P21 supporting cells 5 d after TRULI withdrawal. 
(B) S-phase genes are similarly downregulated. (C) Genes known to be targets of theYap-Tead 
complex are also downregulated. (D) To assess whether new hair cells can be formed after TRULI 
treatment, P21 utricles that had been treated with TRULI for 5 d were cultured for two days to 
allow cell-cycle exit, then transfected with adenovirus carrying Atoh1. The cultures were co-
treated with EdU to permit lineage tracing of supporting cells that had undergone cell division in 
the presence of TRULI. After 5 d of Atoh1 expression, many EdU-positive supporting cells 
















































































Table S1.  Alignment of residues at the ATP-binding sites of AGC kinases. Related to 
Figure 3. These 36 residues define the ATP-binding pockets of 62 kinases, but do not represent 
continuous sequences. 
LATS1        LGIGAFGEVAKVRLFVMDYIPGGDMMSDKDNLTDFG 
LATS2        LGIGAFGEVAKVKLFVMDYIPGGDMMSDKDNLTDFG 
NDR1         IGRGAFGEVAKVKMLIMEFLPGGDMMTDKDNLSDFG 
NDR2         IGRGAFGEVAKVKMLIMEFLPGGDMMTDKDNLSDFG 
ROCK1        IGRGAFGEVAKVQLMVMEYMPGGDLVNDKDNLADFG 
ROCK2        IGRGAFGEVAKVQLMVMEYMPGGDLVNDKDNLADFG 
RSKL2        VQDPATGGTMKSSGPHLNLLTPARLPSDHGNLTYFG 
SgK494       VAKGSFGTVAKHSLIMCSYCSTDLYSLDKENLTDFG 
PDK1         LGEGSFSTVAKVKLFGLSYAKNGELLKDKENLTDFG 
RSK4         LGQGSFGKVAKVKLLILDFLRGGDVFTDKENLTDFG 
RSK1         LGQGSYGKVAKVKLLILDFLRGGDLFTDKENLTDFG 
RSK3         LGQGSFGKVAKVKLLILDFLRGGDLFTDKENLTDFG 
RSK2         LGQGSFGKVAKVKLLILDFLRGGDLFTDKENLTDFG 
p70S6K       LGKGGYGKVAKVDLLILEYLSGGELFMDKENMTDFG 
p70S6Kb      LGKGGYGKVAKVELLILECLSGGELFTDKENMTDFG 
MSK1         LGTGAYGKVAKVTLLILDYINGGELFTDKENLTDFG 
MSK2         LGTGAYGKVAKVTLLILDYVSGGEMFTDKENLTDFG 
YANK2        IGKGSFGKVAKVNLMVVDLLLGGDLRYDKDNLTDFN 
YANK3        IGKGSFGKVAKVNLMVVDLLLGGDLRYDKDNLTDFN 
YANK1        IGKGSFGKVAKVNLMVVDLLLGGDLRYDKDNLTDFN 
PKCi         IGRGSYAKVAKVGLFVIEYVNGGDLMFDKDNLTDYG 
PKCz         IGRGSYAKVAKVGLLVIEYVNGGDLMFDKDNLTDYG 
SGK2         IGKGNYGKVAKVGLFVLDYVNGGELFFDKENLTDFG 
SGK          IGKGSFGKVAKVGLFVLDYINGGELFYDKENLTDFG 
SGK3         IGKGSFGKVAKVGLFVLDFVNGGELFFDKENLTDFG 
PKN3         LGRGHFGKVAKLSLFVTEFVPGGDLMMDKDNLADFG 
PKN2         LGRGHFGKVAKVNLFVMEYAAGGDLMMDKDNLADFG 
PKN1         LGRGHFGKVAKVNLFVMEYSAGGDLMLDKDNLADFG 
AKT1         LGKGTFGKVAKTALFVMEYANGGELFFDKENMTDFG 
AKT2         LGKGTFGKVAKTALFVMEYANGGELFFDKENMTDFG 
AKT3         LGKGTFGKVAKTSLFVMEYVNGGELFFDKENMTDFG 
PKCt         LGKGSFGKVAKTHMFVMEYLNGGDLMYDKDNLADFG 
PKCd         LGKGSFGKVAKTHLFVMEFLNGGDLMYDKDNLADFG 
PKCe         LGKGSFGKVAKTQLFVMEYVNGGDLMFDKDNLADFG 
PKCh         LGKGSFGKVAKTQLFVMEFVNGGDLMFDKDNLADFG 
PKCg         LGKGSFGKVAKTQLFVMEYVTGGDLMYDKDNMTDFG 
PKCb         LGKGSFGKVAKTQLFVMEYVNGGDLMYDKDNMADFG 
PKCa         LGKGSFGKVAKTQLFVMEYVNGGDLMYDKDNMADFG 
BARK2        IGRGGFGEVAKVCMFILDLMNGGDLHYDKANLSDLG 
BARK1        IGRGGFGEVAKVCMFILDLMNGGDLHYDKANLSDLG 
RHOK         LGKGGFGEVAKVSLLVMTIMNGGDIRYDKENLSDLG 
GPRK7        LGKGGFGEVAKVSLLVMSLMNGGDLKFDKENLSDLG 
GPRK6        LGKGGFGEVAKVSLLVLTLMNGGDLKFDKENLSDLG 
GPRK5        LGKGGFGEVAKVNLLVLTIMNGGDLKFDKENLSDLG 
GPRK4        LGKGGFGEVAKVSLLVLTIMNGGDLKFDKENLSDLG 
MAST3        ISNGAYGAVAKVSMMVMEYVEGGDCATDKDNLTDFG 
MAST4        ISNGAYGAVAKVSMMVMEYVEGGDCATDKDNLTDFG 
MAST2        ISNGAYGAVAKVSMMVMEYVEGGDCATDKDNLTDFG 
MAST1        ISNGAYGAVAKVGMMVMEYVEGGDCATDKDNLTDFG 
CRIK         VGCGHFAEVAKPQLLVMEYQPGGDLLSDKENLVDFG 
MASTL        ISRGAFGKVAKVHLLVMEYLIGGDVKSDKDNLTDFG 
DMPK1        IGRGAFSEVAKTQLLVMEYYVGGDLLTDKDNLADFG 
MRCKb        IGRGAFGEVAKTALLVMDYYVGGDLLTDKDNLADFG 
DMPK2        IGRGAFGEVAKTTLLVMDYYAGGDLLTDKDNLADFG 
MRCKa        IGRGAFGEVAKTTLLVMDYYVGGDLLTDKDNLADFG 
PKG2         LGVGGFGRVAKVKLMLLEACLGGELWSDKENIVDFG 
PKG1         LGVGGFGRVAKVRLMLMEACLGGELWTDKENIVDFG 
PRKX         VGTGTFGRVAKIRLMLMEYVPGGELFSDKENLTDFG 
PRKY         MGTGTFGRVAKIRLMLMEYVPGGELFSDKENLTDFG 
PKACg        LGMGSFGRVAKVKLLVMEYVPGGEMFSDKENLTDFG 
PKACb        LGTGSFGRVAKVRLMVMEYVPGGEMFSDKENLTDFG 
PKACa        LGTGSFGRVAKVKLMVMEYVPGGEMFSDKENLTDFG 
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Table S2.  Percentage sequence identity for the 36 residues of the ATP-binding site 
between Lats1 and Lats2 and AGC kinases. Related to Figure 3. In this and the subsequent 









 LATS1 100.0 97.2 
 LATS2 97.2 100.0 
 PKACb 75.0 72.2 
 PKN2 72.2 72.2 
 PKN1 72.2 72.2 
 ROCK1 72.2 72.2 
 ROCK2 72.2 72.2 
 PKACg 72.2 75.0 
 PKACa 72.2 75.0 
 PKCe 69.4 69.4 
 PKCg 69.4 69.4 
 NDR1 69.4 72.2 
 NDR2 69.4 72.2 
 MASTL 69.4 69.4 
 MRCKb 69.4 69.4 
 DMPK2 69.4 69.4 
 MRCKa 69.4 69.4 
 SGK 66.7 66.7 
 PKN3 66.7 66.7 
 PKCt 66.7 66.7 
 PKCd 66.7 66.7 
 PKCh 66.7 66.7 
 PKCb 66.7 66.7 
 PKCa 66.7 66.7 
 MSK1 63.9 63.9 
 MSK2 63.9 63.9 
 CRIK 63.9 63.9 
 DMPK1 63.9 63.9 
 PRKX 63.9 61.1 
 PRKY 63.9 61.1 
 RSK4 61.1 63.9 
 RSK3 61.1 63.9 
 RSK2 61.1 63.9 
 YANK2 61.1 61.1 
 YANK3 61.1 61.1 
 YANK1 61.1 61.1 
 PKCi 61.1 61.1 
 SGK2 61.1 61.1 
 SGK3 61.1 61.1 
 AKT1 61.1 61.1 
 AKT2 61.1 61.1 
 AKT3 61.1 61.1 
 RHOK 61.1 61.1 
 GPRK7 61.1 61.1 
 MAST3 61.1 61.1 
 MAST4 61.1 61.1 
 MAST2 61.1 61.1 
 MAST1 61.1 61.1 
 RSK1 58.3 61.1 
 PKCz 58.3 58.3 
 GPRK6 58.3 58.3 
 GPRK5 58.3 58.3 
 GPRK4 58.3 58.3 
 PDK1 55.6 58.3 
 BARK2 55.6 55.6 
 BARK1 55.6 55.6 
 PKG1 55.6 52.8 
 p70S6K 52.8 52.8 
 PKG2 52.8 55.6 
 p70S6Kb 50.0 50.0 
 SgK494 44.4 44.4 





Table S3.  Target enzymes binding more potently than LATS1. Related to Figure 3. Of 314 
kinases in a binding panel, these enzymes bound 1 µM TRULI more strongly than did Lats1 or 











































Table S4.  Half-maximal inhibitory concentrations (IC50s) of TRULI for selected kinases. 
Related to Figure 3. 
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